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Abstract 
Non-prescribed use of stimulant medications among college students, such as Ritalin®, 
and Adderall®, has become a public health concern. Expectancies, which are beliefs that 
individuals hold regarding the consequences of engaging in a particular behavior, are known to 
play a prominent role in the initiation and maintenance of alcohol and drug use. This study had 
two aims: (1) to determine if an expectancy challenge could reduce participants’ academic 
performance expectancies related to non-prescribed use of stimulant mediations, and (2) to 
determine if change in expectancies mediates consumption of the drug. Seventy-eight 
undergraduate students were randomized to either the expectancy challenge (EC) condition, the 
psychoeducation (PE) condition, or the assessment-only (AO) condition. Results from two 
separate hierarchical linear models (HLM) indicated that there were no significant group 
differences between the EC and PE conditions with regards to change in expectancies (γslope = 
0.19, t(43) = 1.97, p = 0.055) or consumption (γslope = 0.06, t(43) = 1.75, p = 0.09). When the two 
treatment conditions were combined, results from the HLM analyses found a significant effect of 
treatment over control for both expectancies (γslope = -0.25, t(76) = -3.64, p < 0.001) and 
consumption (γslope = -0.07, t(76) = -2.07, p = 0.04). The mediation analysis indicated a non-
significant relationship between the mediating variable (i.e., change in academic expectancies) 
and the outcome variable (change in consumption; γslope = 0.0004, t(76) = 0.098, p = 0.992), 
indicating that mediation was not present. Due to an inferior placebo manipulation, the EC did 
not produce the anticipated results. However, results from the study suggest that the didactic 
component of the EC and PE conditions was effective in modifying expectancies and reducing 
consumption.    
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Efficacy of an Expectancy Challenge to Reduce Non-Prescribed Use of Stimulant Medications 
among College Students 
Methylphenidate and mixed amphetamine salts, commonly known as Ritalin® and 
Adderall®, respectively, are stimulant medications typically used to treat Attention 
Deficit/Hyperactivity Disorder (ADHD). ADHD is marked by a persistent pattern of inattention 
and/or hyperactivity and impulsivity that causes significant impairment (American Psychiatric 
Association, 2000). Stimulant medications are intended to have a calming and focusing effect on 
individuals with ADHD, causing improved attention and concentration. Although stimulant 
medications are the first-line treatments for ADHD (Wilens, Gignac, Swezey, Monuteaux, & 
Biederman, 2006), they also have an abuse potential (Kollins, MacDonald, & Rush, 2001).  
Stimulant medications act on the dopamine neurotransmitter system of the brain. It is 
surmised that individuals with ADHD have lower levels of dopamine than non-ADHD 
individuals, leading to difficulties with attention and concentration, and to hyperactivity. The 
medication acts to increase levels of dopamine, which increases an individual’s level of 
attention. Dosing of stimulant medications is intended to start slowly so that the therapeutic level 
is reached gradually. However, when taken in dosages or routes not prescribed by a physician or 
qualified health provider (i.e., large dosages, intranasal administration), the level of dopamine 
increases rapidly and in an amplified manner similar to other drugs of abuse (National Institute 
on Drug Abuse [NIDA], 2001). This can disrupt normal communication between brain cells, 
increasing the risk of addiction. When stimulant medications are taken at high dosages an 
individual risks developing a dangerously high body temperature, irregular heartbeat, 
cardiovascular failure, seizure, or stroke. When taken repeatedly over a period of time, an 
individual can become hostile and develop feelings of paranoia (NIDA, 2001). 
   
  2 
  
A considerable amount of research exists demonstrating the effectiveness of stimulant 
medications in the amelioration of ADHD symptoms in children, adolescents and adults (Gadow, 
1983; Carlson & Brunner, 1993; Loe & Feldman, 2007; Faraone, Spencer, Aleardi, Pagano, & 
Biederman, 2004). However, there is a lack of evidence demonstrating that stimulant 
medications enhance academic achievement (e.g., earning better grades, better standardized test 
scores) for these individuals (Gadow, 1983; Carlson & Brunner, 1993; Loe & Feldman, 2007). 
Specifically, research with non-ADHD individuals has shown that stimulant medications do not 
improve the areas of working memory related to complex cognitive tasks, such as reading 
comprehension and problem-solving (Conway, Kane, & Engle, 2003; Elliott, Sahakian, 
Matthews, Bannerjea, Rimmer, & Robbins, 1997). Therefore, although students may believe that 
stimulant medications help improve their performance and achievement by enhancing their 
ability to concentrate and study, they are not actually achieving this as a result of taking the 
medication. Despite this, students continue to use the drug. 
In 2008, the Monitoring the Future (MTF) survey revealed that the annual prevalence of 
non-prescribed use of stimulant medications among college students was 3.2%, while their same-
aged non-college peers had a lower prevalence of 2.1% (Johnston, O'Malley, Bachman, & 
Schulenberg, 2009). This is significant in that earlier publications suggested that college-aged 
individuals not enrolled in school had higher rates of misuse and abuse for all illicit substances, 
while enrolled students only had higher rates of abuse of alcohol (Johnston, O’Malley, & 
Bachman, 2003). Moreover, nationwide surveys found that prevalence rates of non-prescribed 
use were as high as 25% at individual universities and that use was associated with higher rates 
of tobacco, alcohol, and illicit drug use, binge drinking, and engaging in other risky behaviors 
(e.g., driving after binging) (McCabe, Knight, Teter, & Wechsler, 2005). Additional studies 
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determined that students’ motivations for use were related to increasing academic performance 
(e.g., improve intellectual performance, help with concentration) and for recreational purposes 
(e.g., to counteract the effects of other drugs, to get high) (Graff-Low & Gendaszek, 2002; 
Barrett, Darredeau, Bordy, & Pihl, 2005; Teter, McCabe, Cranford, Boyd, & Guthrie, 2005; 
White, Becker-Blease, & Grace-Bishop, 2006). Taken together, these data indicate a problem 
that appears to be unique to the college setting. However, despite the information gained from 
these studies, no research has focused on the mechanisms influencing non-prescribed use of the 
medication among college students. One possible mechanism that warrants investigation is 
expectancies.  
Expectancy Theory 
Outcome Expectancy Theory, also called Expectancy Theory, is derived from Social 
Cognitive Theory (SCT; Bandura, 1986). According to Expectancy Theory, behaviors are 
explained in part by individuals’ expectations that a particular effect or outcome will occur as a 
result of performing a certain behavior. It does not matter whether the expectations are logical or 
based on actual experiences; what matters most is that the expectations are held and that, over 
time, they can have reinforcing effects on an individual’s behaviors (i.e., an individual will 
continue to engage in a particular behavior for as long as he/she believes that engaging in the 
behavior will result in a desired result) (Jones, Corbin, & Fromme, 2001).  
Research has provided strong evidence that expectancies are an important factor in the 
initiation and maintenance of alcohol consumption (Christiansen, Goldman, & Inn, 1982), as 
well as in the prediction of future alcohol use (Brown, 1985; Christiansen, Smith, Roehling, & 
Goldman, 1989). Studies of the association between alcohol expectancies and alcohol use have 
shown that the amount consumed and/or the frequency in which alcohol is consumed can be 
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influenced by a person’s expectancies of what might occur in a particular situation in which he or 
she is drinking (Vogel-Sprott, 1983). Similarly, expectancies have been consistently and more 
strongly associated with quantity of consumption than with frequency of consumption, and this 
finding has held true for adolescents, college students, and community samples (Chen, Grube, & 
Madden, 1994; McMahon, Jones, & O’Donnell, 1994; Mooney, Fromme, Kivlahan, & Marlatt, 
1987). Additionally, the expectations that one has about what might occur in a particular 
situation may drive his or her behavior to consume alcohol in a certain manner (Schafer & 
Brown, 1991). Last, there is growing literature indicating that alcohol expectancies mediate 
patterns of alcohol consumption (Darkes, Greenbaum, & Goldman, 2004; Finn, Sharkansky, 
Brandy, & Turcotte, 2000; Henderson, Goldman, Coovert, & Carnevalla, 1994; Sher, Walitzer, 
Wood, & Brent, 1991).  
Little research has focused on examining expectancies that individuals may have for 
other drugs of abuse. A handful of studies aimed to examine possible expectancy effects for 
marijuana, cocaine, and ecstasy and have revealed that expectancies about their effects do exist 
for these drugs (Schafer & Brown, 1991; Engels & ter Bogt, 2004). Additionally, these studies 
also demonstrated associations between expectancies and use. Recently, a drug that has received 
some attention in the area of expectancy research is prescription stimulant medication. In this 
regard, the Stimulant Medication Outcome Expectancy Questionnaire (SMOEQ; Labbe & 
Maisto, 2010) was developed to measure expectancies related to non-prescribed use of stimulant 
medication. The SMOEQ was subjected to exploratory and confirmatory factor analyses, and 
tests of validity and reliability, and results revealed that college students hold expectancies about 
the outcomes of non-prescribed use of stimulant medications that are measurable. 
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The factor analyses of the SMOEQ revealed three distinct factors, or types of 
expectancies: expectancies related to enhancing academic performance, expectancies related to 
recreational use (e.g., to get high), and expectancies related to experiencing negative 
physiological effects from non-prescribed use of the drug. Upon inspection of the items that 
comprise each factor, those loading on the Academic and Recreational factors generally reflect 
positive expectancies (i.e., positive consequences or effects of use), while those items loading on 
the Negative Physiological Effects factor reflect negative expectancies (i.e., negative 
consequences or effects of use).  
Positive and Negative Expectancies 
 Research has established that alcohol expectancies consist of two global factors – positive 
expectancies and negative expectancies (Leigh & Stacy, 1993). Positive expectancies are 
associated with beliefs that pleasurable/desirable effects will occur as a consequence of a 
behavior and have shown to be a robust predictor of drinking patterns (Rohsenow, 1983; Brown, 
1985; Brown, Goldman, & Christiansen, 1985; Stacy, Widaman, & Marlatt, 1990). Positive 
expectancies are also predictive of drinker status (i.e., heavy versus light drinker) (Southwick, 
Steele, Marlatt, & Lindell, 1981; Brown, 1985; Steele & Southwick, 1985), are strongly 
associated with quantity and frequency of alcohol consumption (Stacy et al., 1990; Carey, 1995), 
and can be predictive of problem drinking and/or alcohol dependence (Gilles, Turk, & Fresco, 
2006). On the other hand, negative expectancies are associated with beliefs that non-
pleasurable/undesirable effects will occur as a consequence of a behavior and appear to limit 
consumption and may be predictive of abstention from alcohol (Leigh & Stacy, 2004).  
The principles of immediacy and delay-of-reinforcement have been applied to better 
understand the relationship between positive and negative expectancies and alcohol consumption 
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and drinking patterns. These principles emphasize the strength of immediate over delayed 
outcomes for reinforcement of a behavior (Stacy et al., 1990). Regarding expectancies, it is 
hypothesized that positive expectancies are more strongly associated with the immediate effects 
of alcohol use that are typically perceived as positive (e.g., social facilitation) than with the 
delayed effects that are typically perceived as negative (e.g., cognitive impairment) (Rohsenow, 
1983; Stacy et al., 1990). Furthermore, according to the immediacy principle, positive 
expectancies are more readily retrieved from memory than negative expectancies, because 
positive experiences/outcomes are more likely to have been initially encoded in memory during 
drinking episodes (Stacy et al., 1990). As a result, during subsequent similar drinking episodes, 
positive memories and expectancies are more likely to be retrieved, prompting an individual to 
drink in a manner that produces the positive effects he or she experienced in past drinking 
situations (Rohsenow, 1983; Stacy et al., 1990).   
In addition to alcohol, some research exists examining the role of expectancies on 
marijuana, cocaine, and ecstasy use. In this regard, nonuse of marijuana, cocaine, and ecstasy 
was associated with stronger negative expectancies and consequences, and use of the drugs was 
associated with stronger positive expectancies and consequences (Schafer & Brown, 1991; 
Engels & ter Bogt, 2004; Aarons, Brown, Stice, & Coe, 2001; Hayaki, Anderson, & Stein, 2008). 
Also, an association has been found between high expectations for negative effects and cessation 
of both marijuana and cocaine use (Aarons et al., 2001). The data imply that holding stronger 
positive expectancies regarding the effects of marijuana, cocaine, and/or ecstasy may mediate 
drug use behaviors, while holding negative expectancies may be a protective factor against 
initiation and maintenance of drug use. Given their predictive utility, it seems clear that 
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expectancies may play a significant role in the identification of pre-morbid alcohol and substance 
use problems and may be a worthy target for treatment interventions. 
Expectancy Challenge (EC) Interventions 
 If expectancies are believed to play a causal role in drinking behaviors, then it would be 
predicted that a change in those expectancies would lead to a change in alcohol consumption. 
Based on this hypothesis, an expectancy challenge (EC) paradigm was designed to directly 
manipulate alcohol expectancies.   
The alcohol EC entails informing participants that they will be given either an alcohol or 
placebo beverage, but are not told which beverage they will receive. Once the beverages are 
consumed, participants engage in group activities, such as playing a group game or debating the 
attractiveness of magazine models, which are meant to elicit specific types of expectancies. 
Afterwards, participants indicate the names of the individuals they believe consumed alcohol, 
including themselves, based on behavioral observations made during the activities. Feedback is 
given regarding who actually drank alcohol and who did not, followed by a didactic lecture 
regarding expectancy theory, emphasizing the point that behavioral effects of alcohol may be due 
to both expectancies and pharmacology. Last, participants are asked to monitor expectancy-
provoking situations in their daily lives to reinforce the fact that daily experiences can strengthen 
or lead to the creation of incorrect alcohol expectancies (Massey & Goldman, 1988; Darkes & 
Goldman, 1993; Darkes & Goldman, 1998). Within the context of an expectancy challenge, it is 
presumed that expectancies are the active mechanisms of change where, by modifying one’s 
beliefs or expectancies about the effects of alcohol, modifications in one’s alcohol consumption 
should occur. 
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Several studies have employed the EC paradigm in different populations and have had 
consistent results. The EC demonstrated a reduction in alcohol expectancies and alcohol 
consumption in moderate to heavy drinking young adult males and light to heavy drinking young 
adult females (Massey & Goldman, 1988; Darkes & Goldman, 1993; Darkes & Goldman, 1998; 
Dunn, Lau, & Cruz, 2000; Corbin, McNair, & Carter, 2001; Wiers & Kummeling, 2004; Wiers, 
van de Luitgaarden, van den Wildenberg, & Smulders, 2005; van de Luitgaarden, Weirs, Knibbe, 
& Candel, 2007; Wood, Capone, Laforge, Erickson, & Brand, 2007; Lau-Barraco & Dunn, 
2008). Taken together, these results are consistent with a mediational role of expectancies on 
alcohol consumption and how alcohol consumption can be modified by decreasing positive 
expectancies. Given the association between expectancies, alcohol, marijuana, cocaine, and 
ecstasy use, and the evidence that expectancies related to non-prescribed use of stimulant 
medication exist, it is important to study the role that stimulant medication expectancies play in 
actual consumption, and whether such use can be reduced by modifying expectancies. 
Purpose of Study  
The primary goal of this study was to implement an expectancy challenge trial to college 
students who engaged in non-prescribed use of stimulant medications, with the aim of reducing 
academic performance expectancies and use. This study intended to advance the field in two 
significant ways. First, an EC trial was developed to address a serious public health concern by 
developing both a preventative measure to deter individuals from initiating use of the drug, as 
well as an intervention to treat individuals who are currently misusing the medication. Second, 
given that the current literature on this topic is quite limited, results from this study will add 
depth to this literature by generating opportunities to conduct research that extends beyond basic 
descriptive studies. Due to the lack of experimental research regarding stimulant medication 
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expectancies and use, the alcohol EC trials provide the most direct evidence for the basis of the 
hypotheses for the proposed study. 
This study had two specific aims. The first aim was to determine the efficacy of an 
expectancy challenge to reduce academic performance expectancies related to non-prescribed 
use of stimulant medications among college students. It was hypothesized that there would be a 
significant condition by time interaction on change of academic performance expectancies and 
consumption of medication for participants in the expectancy challenge condition. Specifically, it 
was anticipated that participants in the expectancy challenge condition would demonstrate a 
significant reduction in magnitude of academic expectancies and consumption of medication 
over time compared to participants in two additional conditions.  
 Second, this study utilized a formal test of mediation to determine if expectancies related 
to non-prescribed use of stimulant medication mediated consumption of the drug. 
Method 
Experimental Design 
This study was a randomized controlled trial in which participants were randomized to 
one of three conditions: the expectancy challenge (EC) condition, the psychoeducation (PE) 
condition, or the assessment-only (AO) condition. EC participants attended two cognitive testing 
sessions and at the beginning of the second session were given a placebo Ritalin® pill. At the end 
of the second testing session EC participants were debriefed and received an informational 
lecture regarding Expectancy Theory, with an emphasis on the differences between behavioral 
and pharmacological effects. PE participants also attended two cognitive testing sessions and 
received a didactic lecture regarding Expectancy Theory; however PE participants did not 
receive placebo medication. AO participants only attended two cognitive testing sessions.  
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Prior research has shown that the most common reasons for misusing prescription 
stimulant medications among college students are related to enhancing academic performance, 
such as improved concentration, attention, and memory (Graff-Low & Gendaszek, 2002; Barrett 
et al., 2005; Teter et al., 2005; White et al., 2006). Therefore, this study aimed to challenge 
expectancies related to these reasons through use of cognitive tests that were intended to elicit 
these expectancies. Though other types of expectancies exist related to misuse of stimulant 
medications (i.e., Recreational and Negative Physiological Effects), specifically targeting the 
more commonly held expectancies reaches a wider range of individuals. 
All participants completed four assessment sessions in which the primary outcome 
variables were measured. This included a baseline assessment, a post-test follow-up assessment 
(occurring one week after the second cognitive testing session), a 1-month follow-up assessment 
(four weeks after the post-test), and a 3-month follow-up assessment (12 weeks after the post-
test). Data from all four assessment periods were included in the analyses to model change in 
expectancies and consumption over time. The timing of the three follow-up assessment points 
was chosen for a few specific reasons. First, the alcohol EC studies provide the closest empirical 
precedent regarding the EC design (Darkes & Goldman, 1993; Dunn et al., 2000; Wiers et al., 
2005). According to these guides, a post-test follow-up assessment occurring 1-2 weeks after the 
final intervention session was chosen for the initial follow-up session as a time to begin to assess 
any immediate changes in expectancies and/or consumption. Second, data from these EC studies 
indicate that a 1-month follow-up interval is sensitive to changes in expectancies that are a result 
of the expectancy challenge. Third, three months is a reasonable compromise between the 
practical constraints of following research participants for an extended period of time and 
obtaining initial data on the maintenance of expectancies and consumption that, to date, has not 
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yet been presented. Last, a critique of the alcohol expectancy challenges is that the follow-up 
time period is usually brief (one month or less), and it is recommended that follow-up be 
extended in order to determine if changes seen at the 1-month follow-up will be maintained 
(Wood et al., 2007; Labbe & Maisto, 2011).  
Subjects 
 Based on a power analysis conducted in G*Power (Faul, Erdfelder, Land, & Buchner, 
2007; see Power Analysis section below), a target of 125 male and female Syracuse-area 
undergraduate college students was set for recruitment. Participants were recruited via flyers 
posted on college campuses and advertisements posted on universities’ websites. Eligibility 
criteria to participate were as follows: between the ages of 18 and 24 years, currently an 
undergraduate student, non-prescribed use of stimulant medication within the past 3 months, 
access to a telephone that can be used to complete the post-test and follow-up sessions, and 
proficiency with the English language to ensure comprehension of questionnaires and ability to 
effectively interact with research study personnel. 
 Based on data from Labbe & Maisto (2010), it was anticipated that approximately 458 
students from Syracuse University would call to inquire about the study and approximately 215 
were expected to agree to participate. Recruitment was expected to continue for approximately 
45 weeks, resulting in roughly 5 people per week enrolling in the project.    
General Procedures 
Prospective participants called to determine eligibility. If eligible, they were invited to the 
research lab to go through the informed consent procedure and complete the baseline/first 
cognitive testing session. Participants were greeted by a member of the research staff who 
explained the study and answered any questions the participant had. Once written informed 
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consent was obtained, baseline measures were administered. While the participant completed the 
measures, he or she was randomized, by use of a random numbers table, to one of the three 
experimental conditions. After participants completed the baseline measures, the first set of 
cognitive tests was administered. At the end of the session, the second testing session was 
scheduled for two weeks later. The cognitive tests were scored after the participant left the 
session, and feedback regarding performance was given after completion of the second testing 
session. This procedure was followed so that EC participants, in particular, attributed any 
changes in performance to the drug (actually a placebo) and not to their possibly increased 
motivation to improve their scores. 
The participant returned to the same research lab for the second testing session. The 
research staff member administered the same cognitive tests as were administered in the first 
testing session and scored them immediately after the participant completed the tests. At this 
point feedback was given to the participant regarding his/her performance on the cognitive tests 
from each session. Feedback consisted of telling the participant his/her scores for the tests and 
explaining how the scores compare to other people of his/her age group (Wechsler, 1997). At the 
end of the session a telephone appointment was scheduled for one week later to collect post-test 
measures. 
Because the goal of the expectancy challenge was to confront individuals’ beliefs about 
the pharmacological and behavioral effects of taking stimulant medications, administering 
cognitive tests provided a way to measure one’s cognitive performance on the specific domains 
associated with the most commonly cited reasons for misusing the drug (e.g., to concentrate 
better, to focus better). Therefore, cognitive tests designed to measure an individual’s 
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functioning in these domains were used to determine if an individual’s performance changed as a 
result of believing that he/she received stimulant medication.    
Each participant was called to complete the three follow-up assessments (i.e., the post-
test follow-up assessment, the 1-month follow-up assessment, and the 3-month follow-up 
assessment). During these calls stimulant medication expectancies and use were assessed. 
Previous research has shown that telephone assessments provide the same level of accuracy as 
in-person assessments (Sobell, Brown, Leo, & Sobell, 1996; Rubin, Migneault, Marks, 
Goldstein, Ludena, & Friedman, 2006). Also, this method was utilized to reduce participant 
burden and increase retention. 
All participants, regardless of condition to which they were randomized, completed the 
same battery of cognitive tests at each testing session, and the same set of measures at each 
major assessment point (i.e., baseline, post-test, 1-month, and 3-month). The conditions only 
differed with regards to a specific intervention that may or may not have been part of the 
assigned condition. Details outlining these differences are provided below in the subsections 
describing the specific procedures for each condition. 
All sessions were private, individual sessions. The baseline/first testing session and 
second testing session lasted between 30-45 minutes. The post-treatment, 1- and 3-month follow-
up telephone sessions lasted approximately 15 minutes. Subjects were paid for their 
participation. Students recruited from the Syracuse University introductory psychology 
(PSY205) research subject pool were reimbursed according to the following payment schedule: 1 
credit for the baseline/first testing session, 1 credit for the second testing session, $15 for post-
test and 1-month follow-up calls, and $20 for 3-month follow-up call. In total, PSY205 subject 
pool participants could earn 2 credits and $50. All other subjects were paid according to the 
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following schedule: $10 for the baseline/first testing session, $10 for the second testing session, 
$15 for post-test and 1-month follow-up calls, and $20 for 3-month follow-up call. In total, these 
participants could earn $70.  
Procedures for Expectancy Challenge Participants. The EC condition differed from the 
other two conditions in that participants randomized to the EC condition received placebo 
Ritalin® medication at the beginning of the second testing session. They were told that we were 
interested in examining the effects of Ritalin® on cognitive performance. After they took the pill, 
participants were asked to sit and relax for approximately 15 minutes in order to allow for the 
medication to “take effect.” During this time participants were offered reading materials (e.g., 
newspapers, magazines) as they waited for the time to pass. After 15 minutes elapsed, the second 
cognitive testing session began. After testing, participants were given a questionnaire to measure 
the perceived effects of the medication, perceptions of whether their performance differed from 
the first testing session, and, if so, to what they attributed this change. In this context, what 
mattered most was that participants perceived an increase in performance as a result of taking 
Ritalin®, and that an actual increase in performance was not necessary. Once this information 
was collected, participants were given feedback regarding performance on the tests. Finally, 
participants were debriefed regarding the placebo medication and received an informational 
lecture about Expectancy Theory with an emphasis on the behavioral effects that occur from 
one’s beliefs about taking the medication and the actual pharmacological effects of the 
medication (see Appendix A for EC script). 
To increase credibility of the placebo, participants were weighed prior to placebo 
administration and told that a physician, a consultant for the study, had determined the 
appropriate dosage corresponding to his/her weight that would be sufficient to produce effects 
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that could be observed while performing the cognitive tests. Though the physician was not the 
individual dispensing the placebo, credibility of the manipulation was sustained. In a study by 
Looby and Earleywine (2009), a non-physician administered the placebo Ritalin® and 
preliminary analyses indicated that a majority of participants believed they received active 
medication (personal communication, Allison Looby, 2/24/10).  
Procedures for Psychoeducation Participants. The PE condition differed from the other 
two conditions in that participants randomized to the PE condition only received the 
informational lecture on Expectancy Theory. The focus of the lecture was on behavioral effects 
that occur from one’s beliefs about taking stimulant medication and the actual pharmacological 
effects of the medication. 
Procedures for Assessment-Only Participants. The AO condition differed from the other 
two conditions in that participants randomized to the AO condition only completed the two 
cognitive testing sessions and did not receive any type of intervention.  
Follow-Up 
  All participants were called to complete the post-test, 1- and 3-month follow-up 
measures over the phone. At each session participants completed the SMOEQ and the Substance 
Use Timeline Follow-Back calendar. 
Setting 
 In-person research sessions were private, individual sessions that took place in a research 
laboratory within the Psychology Department at Syracuse University. Telephone assessments 
also were conducted by research staff in the lab space. The research space was private to ensure 
confidentiality of participants. 
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 Undergraduate research assistants (RAs) assisted with recruitment, administration of the 
study protocol, and data management. All RAs were required to be psychology majors at least in 
his/her junior year of college and have a grade point average of at least a 3.0. All RAs were 
required to complete the Collaborative Institutional Training Initiative (CITI) training course and 
the Protecting Human Research Participants course created by the NIH Office of Extramural 
Research to comply with human subjects protections training requirements. Before any RA 
administered any aspect of the study, he or she was thoroughly trained by either the principal 
investigator (PI; Ms. Labbe) or by another graduate student who was trained in the study 
protocol by the principal investigator. All RAs initially observed the PI or the graduate student 
administer the protocol to several participants across each condition. Additionally, each RA 
participated in numerous role-play scenarios with the PI or graduate student to practice 
delivering the protocol and managing any potential issues that a participant may raise. Once it 
was determined that the RA was adequately prepared, the RA administered the study protocol to 
research participants while being observed by the PI or graduate student. These observations 
continued until the RA accurately and repeatedly delivered the protocol to participants in each 
condition. At this point, RAs were finally allowed to administer the protocol independently.  
 To effectively carry out study procedures and bolster study fidelity, the PI provided 
regular supervision, which included weekly meetings with the RAs to review recruitment 
progress, data entry issues, and address any issues that came up while meeting with participants. 
With regards to data entry, the RAs were provided with detailed instructions on how to enter data 
for each variable that was assessed throughout the study. Additionally, all data was double 
entered into two separate data entry spreadsheets and compared on a quarterly (i.e., every three 
months) schedule to check for any data entry discrepancies and all errors were corrected. Though 
   
  17 
  
the RAs were aware that the overall goal of the study was to reduce non-prescribed use of 
stimulant medications among college students, they were not made aware of the specific study 
hypotheses. 
Recruitment Procedures 
 Initially, recruitment methods included posting flyers on and around the Syracuse 
University campus. Additionally, advertisements for the study were posted on the SU Today 
news listserv and large lecture courses were visited during which time the study was briefly 
explained to students and sign-up sheets were provided for students to write their contact 
information if they were interested in receiving a follow-up call to learn more about the study. 
During the first five months of the study, only 47 students inquired about the study and only 14 
(29.7%) were eligible and agreed to participate. This represented an average of 2.35 students 
inquiring about the study per week and only 0.7 students actually enrolling per week during this 
period of time. To enhance recruitment, recruitment methods were revised by making the study 
available to the introductory psychology research subject pool. During the next ten months, an 
additional 140 students inquired about the study but only 54 (38.6%) were eligible and agreed to 
participate. This represented an average of 3.5 students inquiring about the study each week 
during this time period and only 1.35 students enrolling per week. Recruitment methods were 
revised a final time, making the study open to any undergraduate student in the Syracuse area. 
Flyers were posted at SUNY ESF, Onondaga Community College, and LeMoyne College, as 
well as around downtown Syracuse where college-aged students were known to frequently visit. 
During the final three months, 21 students called to inquire about the study and 13 (61.9%) were 
eligible and enrolled in the study. This represented an average of 1.75 students inquiring about 
the study each week, with only 1.08 students enrolling each week during this period. Although 
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recruitment was opened up to all Syracuse-area undergraduate students, no students outside of 
Syracuse University inquired about the study. 
 To reduce potential attrition, all follow-up assessments were conducted via telephone to 
reduce participant burden of returning to the research lab three times. Additionally, this allowed 
more flexibility in scheduling the follow-up calls. Participants were also provided with various 
routes to contact study staff (i.e., email, telephone numbers) so that they could contact the RAs at 
their own convenience. Last, as stated previously, all participants were compensated for their 
time, which was meant to act as an incentive to complete the study protocol. 
Measures and Assessment Procedures 
 Demographics Survey. A general demographics survey was administered at baseline. 
Age, gender, race (American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, and White), ethnicity (Hispanic/Latino, not Hispanic/Latino), 
grade point average, year in college (i.e. freshman, sophomore, etc.), Greek membership 
(fraternity or sorority member), student status (i.e., full-time, part-time), socioeconomic status 
(participants checked an income bracket that best described them), and information regarding 
stimulant medication use (i.e., method of use, how it was acquired) was assessed. (Appendix B) 
 Substance Use Timeline Follow-Back (TLFB; Sobell & Sobell, 1996). The TLFB is an 
interview technique used to gather retrospective reports of daily alcohol and other drug use for a 
designated period of time. Participants were told to start with the day prior to the assessment and, 
going backwards through the calendar, indicate the number of “standard” alcoholic drinks, 
cigarettes, and stimulant medication pills they consumed each day. Although there is currently 
no standard way to assess for quantity of stimulant medication consumed, it is an important 
variable to measure. Prior research suggests that expectancies are more strongly associated with 
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quantity consumed than with frequency of use (Chen et al., 1994; McMahon et al., 1994; 
Mooney et al., 1987). Therefore, thorough probe questions were used in an attempt to obtain the 
most accurate information regarding quantity consumed, such as number of pills used and dosage 
(i.e., milligrams) of the pills. Regarding marijuana use, participants were asked to indicate on 
which days they used the drug. Cigarettes and marijuana were chosen as additional drugs to be 
assessed because it has been found that they are among the most common drugs used by college 
students after alcohol (Johnson et al., 2009). Anchor events (i.e., key dates such as holidays) 
were included on the calendar to serve as memory aids to enhance recall of consumption of 
alcohol and the other drugs. Past research on alcohol and substance use data obtained from the 
TLFB calendar has shown good reliability and validity in adult and college student samples for 
self-report of alcohol and substance use (Maisto, Sobell, Cooper, & Sobell, 1982; Sobell, Sobell, 
Klajner, Pavan, & Basian, 1986; Ehrman & Robbins, 1994; Fals-Stewart, O’Farrell, Freitas, 
McFarlin, & Rutigliano, 2000). The TLFB was administered at baseline to assess for alcohol and 
drug use for the past 3 months, and at all follow-up sessions to assess for alcohol and drug use 
for the period of time since the last TLFB administration (Appendix C). Because the TLFB 
interview in not a standard paper-and-pencil self-report measure, specific attention was paid 
towards thoroughly training the RAs on administering this assessment. As stated previously, the 
RAs were rigorously trained by initially observing several administrations of the TLFB interview 
to actual study participants. Then, the RA practiced administering the TLFB interview several 
times, in role-play scenarios with the PI or graduate student training him or her. Once the RA 
was able to accurately and repeatedly administer the TLFB to the PI or graduate student, then he 
or she administered the interview to study participants while being observed by the PI or 
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graduate student. Finally, after several successful administrations of the TLFB in this setting, the 
RA was permitted to conduct this assessment independently. 
 Stimulant Medication Outcome Expectancy Questionnaire (SMOEQ; Labbe & Maisto, 
2010). The SMOEQ is a 16-item measure that assesses for expectancies related to non-prescribed 
use of stimulant medications among college students. The scale consists of three factors, which 
reflect three general categories of expectancies: Academic, Recreational, and Negative 
Physiological Effects. The total score for the Academic factor was used to test the main 
hypotheses. Reliability of the scale is 0.86. (Appendix D) 
 Effects of medication questionnaire. Created specifically for this study, this questionnaire 
assessed EC participants’ perceived changes in mood and/or attention, beliefs about if and/or 
how performance differed from the first testing session, and their attributions for any differences 
in performance, as a result of taking the placebo medication. Participants were asked to respond 
to each item with a Likert-type scale, ranging from 0-4 (0=Not At All; 4=Very Much). Example 
of items are, “After taking the medication were you able to concentrate better?”, “After taking 
the medication, did you have more energy?”, and “After taking the medication, were you able to 
focus better?” (Appendix E) 
 Cognitive tests.  The Working Memory Index of the Wechsler Adult Intelligence Scales – 
3rd Edition (WAIS-III; Wechsler, 1997) is an index of an individual’s working memory, short-
term memory, ability to sustain attention, auditory processing skills, cognitive flexibility (i.e., 
ability to shift mental operations), and ability to self-monitor (Sattler, 2008). Measures of 
working memory capacity are significantly correlated with performance on more complex 
cognitive tasks, such as reading comprehension and problem-solving (Conway, Kane, & Engle, 
2003). Similarly, working memory capacity reflects the efficiency of executive functions, 
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particularly the ability to concentrate (Engle, Tuholski, Laughlin, & Conway, 1999; Fukuda & 
Vogel, 2009). Because this index assesses several domains that college students give as reasons 
for using prescription stimulant medication (e.g., to concentrate better, to focus better; Graff-
Low & Gendaszek, 2002; Barrett et al., 2005; Teter et al., 2005; White et al., 2006), the 
cognitive tests used for the proposed study targeted these domains. The following WAIS-III 
subtests were administered: 
 Digit Span. This subtest assesses working memory, memory span, concentration, ability 
to self-monitor, and cognitive flexibility. It consists of two parts, Digits Forward and Digits 
Backward. Digits Forward contains a series of strings of numbers ranging in length from 2 to 9 
digits. Digits Backward contains a series of strings of numbers ranging in length from 2 to 8 
digits. With Digits Forward, the administrator reads a string of numbers, and the examinee is 
asked to repeat the digits in the order in which they were presented. With Digits Backward, the 
administrator reads a string of numbers, but this time the examinee is asked to repeat the digits in 
reverse from which they were given. Correct trials are added together to derive a total raw score 
for the test. Digit Span is a reliable test (r=0.90), and reliability coefficients range from 0.84 to 
0.93 for each age group (Sattler, 2008). (Appendix F) 
 Letter-Number Sequencing. This subtest is a test of auditory working memory, 
concentration, attention, and the ability to consciously retain information, manipulate it, and 
produce a result. It consists of 7 items, and each item contains 3 trials. On each trial, the 
administrator reads a string of a combination of letters and numbers. The examinee is required to 
sequentially order the series of letters and numbers in a specified random order, such as saying 
all the numbers first, in numerical order, followed by the letters, in alphabetical order. Correct 
trials are added together to derive a total raw score. Letter-Number Sequencing is a reliable test 
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(r=0.82), and reliability coefficients range from 0.75 to 0.88 for each age group (Sattler, 2008). 
(Appendix G) 
 Although not impervious to practice effects, these WAIS-III subtests demonstrate good 
test-retest reliability. A panel of scientist-practitioners was commissioned by The Psychological 
Corporation to examine the standardization, norms development, and reliability and validity 
scores of the WAIS-III subtests and index scores. Test-retest stability scores were assessed for 
each subtest, and the results were presented by age group. Each subtest was administered twice, 
with a test-retest interval ranging between 2 and 12 weeks (mean interval=34.6 days). Results for 
the 16-29 year-old age group showed that the test-retest correlations for the Digit Span subtest 
and Letter-Number Sequencing subtest were 0.83 and 0.70, respectively (The Psychological 
Corporation, 1997).   
A summary of the measures that were collected, and at which time points, is presented in 
Table 1.   
Hypotheses  
This study had two main hypotheses: 
 Hypothesis 1: There would be a significant condition by time interaction on change of 
expectancies and consumption of medication. Specifically, it was hypothesized that participants 
in the EC condition and PE condition would demonstrate similar reductions in academic 
expectancies at post-test, but only participants in the EC condition would maintain this reduction 
over time. Further, participants in the EC condition and PE condition would demonstrate a 
reduction in non-prescribed use of stimulant medications by 1-month follow-up, but only 
participants in the EC condition would maintain this reduction in use at the 3-month follow-up. It 
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is hypothesized that participants in the AO condition would not demonstrate any reduction in 
expectancies or consumption. 
Hypothesis 2: It was hypothesized that the relationship between EC condition and 
consumption at the 3-month follow-up would be attenuated when change in academic 
expectancies at 1-month follow-up was included in the model.  
Data Analysis Plan 
Power Analysis.  To establish a target sample size, a power analysis for a 3 (condition) x 
4 (time) between-within-subjects repeated measures analysis of variance (ANOVA) utilizing 
G*Power software (Faul et al., 2007) was conducted. Results from the analysis indicated that, for 
a medium effect size (0.3) with alpha set at 0.02 a total sample size of 42 (i.e., 14 subjects per 
condition) is required to obtain power = 0.8 and detect effects of the analysis aimed to test the 
first hypothesis. An effect size of 0.3 was chosen for the power analysis because previous 
research utilizing the expectancy challenge paradigm to modify alcohol expectancies and reduce 
alcohol consumption found medium within-group and between-group effects sizes (Darkes & 
Goldman, 1993; Corbin et al., 2001; Lau-Barraco & Dunn, 2008). Since three planned pairwise 
comparisons between conditions were to be made (i.e., EC vs. AO, EC vs. PE, and PE vs. AO), 
to keep the experimentwise alpha level equal to 0.05, a Bonferroni adjustment was made, leading 
to an alpha level of 0.0167 (i.e., 0.05/3). This alpha level was utilized in the power analysis to 
derive a target sample size. Longitudinal modeling, which is described below, allows for greater 
power using all available data. Because an ANOVA is a more conservative analysis than 
hierarchical linear modeling, results from this power analysis was used to ensure that a large 
enough sample size was obtained for the study. 
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 The literature was examined to find an empirical guide to determine the appropriate 
sample size needed to conduct the mediation analyses. Through use of the Monte Carlo 
simulation methodology, Fritz & MacKinnon (2007) found that, when using the tests of indirect 
effects to establish the mediated effect (see Hypothesis 2 below for full explanation), detecting 
power = 0.8 and a medium effect size (0.3), requires an approximate sample size of 94. 
 Attrition. Because the proposed project is a longitudinal study some attrition was 
expected. The average attrition rate across all the previous alcohol ECs that included at least one 
follow-up session was 24.2% (Darkes & Goldman, 1998; Keillor et al., 1999; Dunn et al., 2000; 
Corbin et al., 2001; Musher-Eizenman & Kulick, 2003; Wiers & Kummeling, 2004; Wiers et al., 
2005; van de Luitgaarden et al., 2006; Wood et al., 2007; Lau-Barraco & Dunn, 2008). A highly 
conservative attrition rate of 30% was utilized for this study, ultimately leading to a target 
sample size of 125 participants enrolled in the study, with the goal of 96 participants completing 
the entire protocol.   
Data Preparation. All variables were examined for missing data and outliers. The data 
were also examined for normality by analyzing scatterplots and boxplots of the data. Though 
Tabachnick and Fidell (2007) recommend excluding outliers that stand three standard deviations 
above or below the mean, this can potentially lead to a substantial reduction in sample size. 
Therefore, an alternative is to use a modern robust statistic to manage significant outliers without 
eliminating them (Erceg-Hurn & Mirosevich, 2008). Modern robust statistics are a set of 
procedures that are able to maintain Type I error and maintain the power of the test, even when 
assumptions of normality and homoscedasticity are not met (Erceg-Hurn & Mirosevich, 2008). 
Robust statistics are advantageous over traditional transformation procedures, such as logarithm 
or square root transformations, because such traditional procedures often do not establish 
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normality or homoscedasticity after the transform, they do not adequately handle outliers, and 
they can make interpretation of results difficult. In fact, modern robust statistics were developed 
to explicitly address these issues and to perform well even when assumptions are not met (Erceg-
Hurn & Mirosevich, 2008). For the present study, the Winsorized variance of the scores for main 
outcome variables was utilized. The Winsorized variance is advantageous because it is more 
resistant to outliers, leading to more accurate estimations of the standard error terms (Erceg-Hurn 
& Mirosevich, 2008). With this approach, a distribution’s variance is replaced with the 
Winsorized variance. This is accomplished by conducting a 20% trim of the lowest and highest 
scores of the distribution based on the distribution’s mean, and replacing the trimmed scores with 
the lowest and highest untrimmed score. For example, consider that 10 participants obtained the 
following scores on the dependent variable (which have been re-ordered from lowest to highest): 
1, 3, 5, 6, 7, 10, 11, 12, 75, 75. Next, using a 20% trim, the lowest and highest 20% of scores are 
removed from the data set, in this case 1, 3, 75, and 75. Third, the trimmed scores are replaced 
by the lowest untrimmed and highest untrimmed scores, 5 and 12, respectively. In the end, the 
final, Winsorized scores are: 5, 5, 5, 6, 7, 10, 11, 12, 12, 12. Finally, the distribution’s mean and 
variance is re-calculated based on the Winsorized scores. 
Means for all baseline variables were compared through use of one-way analyses of 
variance (ANOVAs) for continuous variables, and chi-square tests for categorical variables, to 
test for baseline differences between groups. A post-hoc Tukey test was conducted to follow-up 
any significant main effects found by the ANOVA or chi-square tests to determine which groups 
significantly differed from each other. The Tukey test was chosen because it makes all possible 
pairwise comparisons while exercising control over alpha, therefore reducing the possibility of 
making a Type 1 error. Though the Scheffé post-hoc test is more conservative with regards to the 
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critical value needed to detect a significant group difference, the Tukey test is preferable when 
only pairwise comparisons are being made, as the Scheffé test is less sensitive to simple pairwise 
comparisons (Howell, 1997).    
Data Analytic Plan to test Primary Hypotheses. Hierarchical linear modeling (HLM), 
which is a form of ordinary least squares (OLS) regression and is used to analyze variance 
associated with the outcome variables when the predictor variables are at different hierarchical 
levels (Woltman, Feldstain, MacKay, & Rocchi, 2012), was utilized to test the primary 
hypotheses. HLM has two defining features: (1) the data are hierarchically structured, starting 
with first-levels units nested within second-level units and so on, and (2) the parameters are 
viewed as having a hierarchical linear structure, meaning that the parameters used to characterize 
the linear relationships occurring between the level-1 units are viewed as varying across level-2 
units as a function of level-2 characteristics (Raudenbush, 1993). HLM is more efficient at 
accounting for variance among variables at different levels than other existing analytic methods 
because it can simultaneously examine relationships within and between hierarchical levels of 
grouped data (Woltman et al., 2012).   
Hierarchical linear modeling uses maximum likelihood (ML) estimation to estimate 
population parameters and test hypotheses about model fit. Further, because of its use of ML 
estimates, HLM can handle well missing data. HLM does not impute missing data but rather 
estimates population parameters using an iterative full ML approach based on existing data for 
each individual. This method of adjusting for missing data is preferable to listwise (casewise) or 
pairwise deletion, as these methods decrease one’s sample size and thus the precision of the 
model estimates. Similarly, full ML estimates are preferable to imputing values based on means, 
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because imputation may also lead to biased and imprecise model estimates (Sarkisian, retrieved 
8/7/12).  
Given that HLM can accommodate issues such as non-independence of observations, 
which exists in repeated measures designs, a lack of sphericity, missing data, small sample sizes, 
and heterogeneity of variances across repeated measures (Woltman et al., 2012), this analytic 
approach was most suitable for analyzing the data and testing the hypotheses of this study.     
Hypothesis 1. To test the first primary hypothesis that there would be a significant 
condition by time interaction on change of Academic expectancies and consumption of 
medication, two separate, two-level linear models were tested.  
The structure of the HLM models is provided by the following equations where i refers to 
the scores of the repeated measurement and j refers to the individual in which the scores of 
repeated measures are nested: 
Level 1 Model 
Yij  =  β0j + β1j*(Time) + ε 
Level-2 Model 
  β0j (intercept) = γ00 + γ01*(Condition) + µ0j 
  β1j (slope)  =  γ10 + γ11*(Condition) + µ1j 
where, in the Level-1 model:  
Yij = dependent variable measured for the ith level-1 unit nested within the jth level-2 
unit  
β0j = intercept for the jth level-2 unit 
β1j = regression coefficient for the slope associated with time for the jth level-2 unit 
ε = random error associated with the ith level-1 unit nested within the jth level-2 unit.  
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In Level-2 model: 
β0j = intercept for the jth level-2 unit 
β1j = regression coefficient for the slope associated with time for the jth level-2 unit  
γ00 = overall mean intercept adjusted for Condition 
γ01 = regression coefficient associated with Condition relative to the level-1 intercept  
β1j = slope for the jth level-2 unit 
γ10 = overall mean intercept adjusted for Condition 
γ11 = regression coefficient associated with Condition relative to the level-1 slope 
µ0j = random effects of the jth level-2 unit adjust for Condition on the intercept 
µ1j = random effects of the jth level-2 unit adjust for Condition on the slope     
For both analyses, the level-1 (within-individual) model included the time variable 
(weeks since baseline), which provided the structure of the model for the outcome variable of 
interest (Yti), either change in expectancies or consumption. These individual growth models 
represented the change that each member of the population is predicted to experience during the 
time period under study. The level-2 (between-individual) models tested the significance of the 
treatment effect, which was estimated from the significance of the slope associated with the 
random assignment variable. These models described the relationship between inter-individual 
differences in the change trajectories (i.e., random effects) and time-invariant characteristics of 
the individual (i.e., fixed effects). Stimulant medication user status (i.e., heavy vs. light) and 
gender were planned to serve as covariates. User status was determined by a median split of the 
sample, resulting in a light use group that consumed medication on 5 or fewer days at baseline 
and a heavy use group that consumed medication on 6 or more days at baseline. 
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User status was used as a covariate because previous research regarding alcohol 
expectancies has shown that expectancies are more strongly associated with quantity consumed 
rather than frequency of use (Chen et al., 1994; McMahon et al., 1994; Mooney et al., 1987) and 
are predictive of drinker status (Southwick et al., 1981; Steele et al., 1985). Therefore, this 
variable was entered as a covariate in the analyses. Gender was also used as a covariate because 
previous literature on misuse of stimulant medication suggests that gender differences may exist 
between types of expectancies endorsed, with women more likely to misuse the drug to cope 
with pressures related to academic activities and men more likely to misuse the drug while 
drinking alcohol and/or to get high (Hall, Irwin, Bowman, Frankenberger, & Jewett, 2005). In 
sum, this model tested that participants varied in their rate of change in magnitude of academic 
expectancies and stimulant medication consumption and that condition predicted variance in 
change of expectancies and consumption. 
Results of HLM level-2 output are interpreted such that coefficients listed correspond to 
whichever condition is coded as “0”. If there are only two levels for condition, a significant p-
value for this fixed effect would indicate which level of condition demonstrated a steeper slope 
over time. However, in the case where there are more than two levels, which is the case in this 
study for condition, a significant p-value indicates a significant difference between condition 
levels but does not indicate which condition has the steepest slope (e.g., fastest change in 
expectancies over time). To address this issue, planned comparisons between condition groups 
were made. Given that it was hypothesized that participants in the EC condition would 
demonstrate a greater reduction in academic expectancies and consumption than participants in 
the PE condition, a planned comparison was conducted where AO participants were excluded 
from the analyses and a comparison between the PE condition and EC condition was conducted 
   
  30 
  
(i.e., PE vs EC). In this scenario, PE was coded “0” and EC was coded “1.” Second, since the PE 
and EC conditions both delivered a type of intervention, a planned comparison was conducted 
looking at no treatment versus treatment (i.e., AO vs PE+EC). In this case, the AO condition was 
coded “0” and the combined PE+EC condition was coded “1”. 
Hypothesis 2. The second hypothesis was that the relationship between the EC condition 
and consumption of medication at 3-month follow-up would be attenuated when change in 
expectancies at 1-month follow-up was considered. The 3-month follow-up time point was 
chosen as the endpoint for the mediation analysis for two primary reasons. First, the goal of the 
mediation analysis was to determine if changes in academic expectancies mediated future 
consumption of the drug rather than current consumption. Therefore, the 3-month follow-up time 
point was used as the endpoint for the mediation analysis instead of the 1-month follow-up time 
point. Second, given the evidence from the field of alcohol expectancies research, heavy drinkers 
have more inflexible expectancies as a result of numerous experiences with alcohol (Christiansen 
et al., 1982). Translating this notion to the area of expectancies related to non-prescribed use of 
stimulant medications, college students’ numerous experiences with consuming the medication 
for academic purposes may lead to more strongly held beliefs. Accordingly, it may require more 
time for considerations to change consumption habits to occur, as well as more time for any such 
change to be implemented. To allow time for this change to occur, the 3-month follow-up time 
point was chosen for the mediation analysis instead of the 1-month follow-up.  
According to Baron and Kenny (1986), mediation occurs when the following three 
conditions are met: (1) variations in levels of the independent variable significantly account for 
variations in the presumed mediator (path a), (2) variations in the mediator significantly account 
for variations in the dependent variable (path b), and (3) when paths ‘a’ and ‘b’ are controlled, a 
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previously significant relationship between the independent and dependent variables is no longer 
significant (path c; see Figure 1). 
Following MacKinnon (MacKinnon, 2008; MacKinnon & Fairchild, 2009), mediation 
can be investigated by conducting three regression equations: (1) regressing the dependent 
variable (DV) on the independent variable (IV), which produces the parameter that describes the 
relation between the DV and the IV, (c), (2) regressing the DV on the IV and the mediator 
variable (MV), which produces the parameter that describes the relation between the MV and the 
DV adjusted for the effects of the IV, (b), and the parameter that describes the relation between 
the IV and DV adjusted for the effects of the MV, (c'), and (3) regressing the MV on the IV, 
which produces the parameter that describes the relation between the IV and the MV, (a). Once 
these parameters are known, the mediated effect can be tested by multiplying the a-path 
regression coefficient with the b-path regression coefficient. Significance is determined by 
dividing the ab product by its standard error and comparing this value to a standard normal 
distribution (MacKinnon et al., 2002).  
Given the nested design of this study, a multilevel mediational analysis, utilizing 
hierarchical linear modeling, was conducted to test each step outlined by MacKinnon. A Monte 
Carlo calculator (Preacher & Selig, 2010), which calculates simulated ab values and associated 
confidence intervals for multilevel mediation, was used to test for significance of a mediated 
effect. 
Four separate analyses were performed to test for mediation. In Step 1, which was 
conducted to determine a significant relationship between the independent variable (i.e., 
condition) and the dependent variable (i.e., consumption of stimulant medication at 3-month 
follow-up; c-path), consumption was entered at the level-1 outcome variable, and condition was 
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entered as the level-2 outcome variable. In Step 2, which was conducted to test for a significant 
relationship between the IV (i.e., condition) and the mediating variable (change in academic 
expectancies from baseline to 1-month follow-up; a-path), academic expectancies was entered as 
the level-1 outcome variable, and condition was entered as the level-2 outcome variable. In Step 
3, which was done to establish a significant relationship between the MV and the DV (b-path), 
consumption was entered as the level-1 outcome variable, and academic expectancies change 
score from baseline to 1-month follow-up was entered as the level-2 outcome variable. Finally, 
in Step 4, which was carried out to verify that the initial significant relationship between the IV 
and DV ascertained in Step 1 was either reduced or became non-significant when the MV was 
entered into the model (c’-path), consumption was entered as the level-1 outcome variable, and 
condition and academic expectancies change score was entered as the level-2 outcome variables. 
Unfortunately, HLM is unable to predict the slope for one variable based on the slope of 
another variable, and such was the case in testing the relationship between the mediating variable 
and the dependent variable (b-path). Therefore, modeling the slope associated with change in 
stimulant medication consumption from baseline to 3-month follow-up based on the slope 
associated with change in academic expectancies from baseline to 1-month follow-up could not 
be done. To account for this problem, a change score was calculated for academic expectancies 
that was utilized as a proxy in order to test the relationship between the mediating variable and 
the dependent variable. This approach has been used by others and has been accepted in the field 
(Ironson, O’Cleirigh, Fletcher, Laurenceau, Balbin, Klimas, Schneiderman, & Solomon, 2005). 
For all HLM models, all continuous variables in the level-2 models were centered around 
their group means, and all dichotomous variables were coded 1/0. Due to the presence of several 
significant outliers and significant skew for both primary outcome variables, both variables were 
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Winsorized and the Winsorized values were used for all HLM analyses. Additionally, because 
HLM will not include any observations with missing data at level-2, which thus reduces sample 
size and power, level-2 data were imputed as needed. This occurred only with regards to 
calculating the change score for academic expectancies for the mediation analysis. Forty-three 
participants had data for academic expectancies at the 1-month follow-up. The mean was 
calculated and imputed for the remaining 35 participants that had missing data for this 
assessment period. Last, though the consumption variable was intended to reflect quantity of 
stimulant medication consumed, a reliable consumption variable based on quantity could not be 
calculated. Quantity of medication consumed was assessed with each participant, however 
participants often could not recall how many pills they took on an occasion, nor could they 
confidently recall the dosage of the medication they took. Further, students often reported taking 
various types of stimulant medication formulations, such as immediate release and 
sustained/extended release, and an array of different medication brands, including Ritalin®, 
Adderall®, Vyvanse®, and Concerta®. Each of these medications has different dosage schedules, 
for example, Vyvanse® capsules range from 20mg – 70mg, Adderall pills range from 5mg – 
40mg, and Ritalin pills range from 5mg-60mg. Given these differences, averaging across the 
diverse medications that students use would not result in an accurate consumption variable. As a 
result, based on data collected from the time-line follow-back interview, a consumption variable 
was created that reflected the number of days a participant consumed the medication. 
Model parameters were estimated by a full maximum-likelihood estimation with robust 
standard errors. Unconstrained models were first tested to confirm individual variation around 
the slope and intercept before testing the effect of treatment. Last, effects sizes for HLM 
estimates were calculated for statistically significant outcomes using the formula dGMA-raw = 
   
  34 
  
γ11(time)/SDraw, where γ11 is the fixed effects slope coefficient associated with the predictor, 
condition, time is the total number of weeks of the study, and SDraw is the standard deviation 
associated with the random effects slope coefficient at level-1 (Feingold, 2009). Cohen’s d 
conventions were used to determine small (0.2), medium (0.5), and large (0.8) effect sizes.      
Results 
Participant Characteristics 
 Participant flow throughout the study is depicted in Figure 2. A total of 78 students 
consented and were randomized into the study. The mean age of the sample at baseline was 19.5 
years (SD=1.39), 52.6% (n=41) were male, and had a mean GPA of 3.10 (SD=0.50). A majority 
of the subjects were Caucasian (66.7%, n=52), not Latino (89.7%, n=70), and were not affiliated 
with Greek life (69.2%, n=54). One-third of the sample identified as freshmen, and another third 
identified as sophomore. The mean score on the Academic subscale of the Stimulant Medication 
Outcome Expectancy Questionnaire was 46.1 (SD=6.36; maximum possible score is 56), and the 
mean number of days stimulant medications were used in the 90 days prior to the baseline 
assessment was 10.67 (SD=16.15). See Table 2 for participant demographics, Table 3 for 
correlations between primary outcome variables, Table 4 for test-retest reliability statistics for 
the SMOEQ, Table 5 for cognitive test scores, and Figures 3 and 4 for a graphic representation 
of academic expectancies and stimulant medication consumption over time by condition, 
respectively.  
One-way analyses of variance (ANOVAs) and chi-square tests were conducted to 
determine the presence of any significant group differences between the conditions on all 
baseline variables. Significant group differences were found for GPA (F(2,71)=3.47, p=0.036). A 
follow-up post-hoc Tukey test determined that the significant group difference occurred between 
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participants in the PE and EC conditions, with subjects in the PE condition having a statistically 
significantly higher mean GPA at baseline than subjects in the EC condition (p=0.05; M=3.25 
and M=2.90, respectively). Additionally, a significant group difference was found for the total 
number of days marijuana was used in the 90 days prior to the baseline assessment 
(F(2,75)=3.42, p=0.038). However, a follow-up post-hoc Tukey test did not find any significant 
differences when explicitly comparing group means, though there was a trend towards 
significance between participants in the PE and EC conditions such that subjects in the PE 
condition used marijuana, on average, a greater numbers of days than subjects in the EC 
condition (p=0.065; M=38.38 and M=16.85, respectively). Aside from these two variables, no 
other significant group differences were found for any of the other baseline variables. 
Because user status was hypothesized to be a significant covariate, additional chi-square 
analyses were conducted to determine if there were any group differences with regards to score 
for academic expectancies and frequency of consumption. The analyses found that heavy users 
were more likely to have a higher average score for academic expectancies at baseline (M = 46.7, 
SD = 5.57) than light users (M = 45.4, SD = 7.03; χ2(20) = 31.77, p = 0.046), and more likely to 
consume stimulant medications on a greater number of days at baseline (M = 19.3, SD = 19.9) 
than light users (M = 2.5, SD = 1.34; χ2(23) = 78.0, p < 0.0001).  
Retention rates for the study were low, with only 58.9% (n=46) retained through the post-
test assessment, 55.1% (n=43) retained through the 1-month follow-up, and only 38.5% retained 
through the 3-month follow-up (n=30). Attrition analyses comparing completers to non-
completers on baseline measures found a significant difference on total days stimulant 
medications used in the 90 days prior to the baseline assessment, with non-completers using the 
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medication on more days than completers (F(1,76)=6.51, p=0.013). Additionally, the analyses 
found that women were more likely than men to be completers (χ2(df=1)=13.11, p<0.001).  
Hypothesis 1   
Academic Expectancies. In the first planned comparison (PE vs EC), the level-1 analysis 
demonstrated a significant linear decline in academic expectancies, γslope = -0.49, t(46) = -9.98, p 
< 0.001, during the study period, indicating a decrease in academic expectancies for study 
participants as a whole. This model indicated that the average academic expectancies score at 
study entry was 45.8, and this decreased at a rate of 0.49 points/week (about 7.35 points/15 
weeks). There was no significant individual variation about the slope, ρslope = 0.04, df(28), χ2 = 
19.50, p > 0.50. For level-2, condition, along with same two covariates (i.e., GPA and number of 
days marijuana was used prior to the baseline assessment), were added to the model. Results of 
adding condition and the covariates to the model indicated that condition was not significantly 
related to change in academic expectancies over time, though there was a trend towards 
significance (γslope = 0.19, t(43) = 1.97, p = 0.055; see Table 6). This finding suggests that 
subjects in the EC condition declined at a slower rate with regards to their academic 
expectancies, compared to subjects in the PE condition. Though marijuana use was not 
significantly related to change in expectancies (p = 0.17), GPA was, γslope = -0.14, t(43) = -2.23, 
p = 0.03. The finding for GPA indicates that every 0.14-point decrease in GPA was related to a 
more rapid decline in expectancies. 
 The level-1 analysis of the second planned comparison (AO vs PE+EC) similarly found a 
significant linear decline in academic expectancies, γslope = -0.39, t(77) = -9.97, p < 0.001, during 
the study period, indicating a decrease in academic expectancies for study participants as a 
whole. This model indicated that the average academic expectancies score at study entry was 
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46.4, and this decreased at a rate of 0.39 points/week (about 5.85 points/15 weeks). There was no 
significant individual variation about the slope, ρslope = 0.08, df(54), χ2 = 46.82, p > 0.50. For the 
level-2 analysis, only condition was added to the model. Because the covariates showed 
significant group differences only between members of the PE and EC conditions, and both 
conditions were combined for this particular analysis, the covariates were not added. Results of 
the level-2 analysis found a significantly greater decrease in academic expectancies over time in 
the treatment condition than in the control condition, γslope = -0.25, t(76) = -3.64, p < 0.001. This 
result shows that academic expectancies declined ¼ of a point faster each week for participants 
in the treatment condition compared to those in the control (i.e., 7.5 points/15 weeks vs. 3.75 
points/15 week; dGMA-raw = 1.39; see Table 6).   
 In sum, the results of the HLM analyses examining treatment effects on academic 
expectancies found that (1) there was no significant difference in rate of decline in expectancies 
between the PE and EC conditions, (2) there was a significant difference in rate of decline in 
expectancies between the AO condition (i.e., control) and the PE and EC conditions (i.e., 
treatment) combined such that participants in the treatment condition declined at a steeper rate 
than those in the control condition, and (3) the combined PE and EC conditions demonstrated a 
large treatment effect size. 
 Stimulant Medication Consumption. Results of the first planned comparison (PE vs. EC) 
with consumption as the outcome variable were similar to those with academic expectancies as 
the outcome variable. The level-1 analysis demonstrated a significant linear decline in number of 
days of consumption during the study period, γslope = -0.41, t(46) = -8.39, p < 0.001, indicating a 
decrease in stimulant medication consumption for study participants as a whole. This model 
indicated that average number of days of stimulant medication consumption at study entry was 
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4.78 days, and this decreased at a rate of 0.41 days/week (about 6.2 days/15 weeks). There was 
also significant individual variation about the slope, ρslope = 0.22, df(28), χ2 = 43.00, p = 0.04. 
Condition and the covariates were added to the level-2 model. Results of this analysis indicated 
that condition was not significantly related to change in consumption over time (γslope = 0.06, 
t(43) = 1.75, p = 0.09; see Table 7). This finding suggests the rate of consumption over time did 
not significantly differ between the two conditions. Unlike the results for academic expectancies, 
results from this planned comparison found that GPA was not significantly related to change in 
consumption (p = 0.12); however marijuana use was, γslope = 0.002, t(43) = 2.04, p = 0.05. This 
finding suggests that there is a linear relationship between marijuana use at baseline and change 
in days of consumption over time such that as the number of days of marijuana use increased, the 
rate of decline in number of days stimulant medications were consumed slowed. 
 Finally, level-1 results of the second planned comparison (AO vs. PE+EC) revealed a 
significant linear decline in days of consumption, γslope = -0.32, t(77) = -8.71, p < 0.001, 
indicating a significant decrease in consumption over the course of the study for participants as a 
whole. This model indicated that the average number of days of stimulant medication 
consumption at study entry was 4.27 days, and this decreased at a rate of 0.32 days/week (about 
4.8 days/15 weeks).  Additionally, results of the level-1 analysis indicated significant individual 
variation about the slope (ρslope = 0.19, df(53), χ2 = 72.43, p = 0.04). When adding condition to 
the level-2 model, results showed that subjects in the treatment condition decreased the number 
of days of consumption at a greater rate compared to subjects in the control condition (γslope = -
0.07, t(76) = -2.07, p = 0.04; 5.3 days/15 weeks vs. 4.14 days/15 weeks; dGMA-raw = 0.49; see 
Table 7). 
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 Overall, results from the HLM analyses examining treatment effects on number of days 
of stimulant medication consumption paralleled the overall results for academic expectancies. 
There was no significant difference in rate of decline in consumption between the PE and EC 
conditions; however there was a significant difference in rate of decline in consumption between 
the AO condition (i.e., control) and the PE and EC conditions (i.e., treatment) combined such 
that participants in the treatment condition declined at a steeper rate than those in the control 
condition. Last, the combined treatment conditions demonstrated a medium effect size. 
 Sex and user status were initially intended to be included as covariates in the model 
examining the effects of condition on change in academic expectancies and stimulant medication 
consumption. However, because there were no significant baseline differences across conditions 
for these two variables, they were not included in the final models. Nevertheless, analyses were 
conducted with the covariates included and the model results did not differ. Therefore, the more 
parsimonious models were reported. 
Hypothesis 2 
 Mediation. Results from Steps 1 and 2 of the HLM analyses testing for mediation found 
that condition (EC+PE) was significantly related to a decrease in the number of days of stimulant 
medication consumption (γslope = -0.077, t(76) = -2.067, p = 0.042) and that condition was 
significantly related to a decrease in academic expectancies (γslope = -0.399, t(76) = -2.778, p = 
0.007), establishing that the first two conditions for mediation were met (i.e., significant c-path 
and significant a-path; see Table 8). Results from Step 3 of the test for mediation showed a non-
significant relationship between change in academic expectancies and consumption at the 3-
month follow-up (γslope = 0.0004, t(76) = 0.098, p = 0.992), indicating that the condition of a 
significant b-path was not met. Finally, results from Step 4 showed that the previously significant 
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relationship between condition and consumption did not decrease in significance when the 
mediating variable was included in the model (γslope = -0.079, t(76) = -2.131, p = 0.036), and that 
the relationship between academic expectancies and consumption remained non-significant (γslope 
= 0.0017, t(76) = 0.443, p = 0.659). Thus the required conditions for the c’-path were not met 
(see Table 6 for mediation results). In sum, only two of the four conditions (i.e., significant c-
path and a-path) necessary to infer the presence of mediation were met. As such, given the data, 
it was concluded that change in academic expectancies from baseline to 1-month follow-up did 
not mediate change in consumption of stimulant medication from baseline to 3-month follow-up.  
Discussion 
Non-prescribed use of stimulant medications, such as Ritalin® and Adderall®, especially 
among college students, has become a growing public health concern. The purpose of the present 
study was to implement an expectancy challenge to college students who engage in non-
prescribed use of stimulant medications with the goal of reducing academic-related expectancies 
and consumption. The study had two primary aims: (1) to determine the efficacy of the 
expectancy challenge in the reduction of academic expectancies and consumption and, (2) to 
determine if expectancies related to non-prescribed use of stimulant medications mediated 
consumption of the drug. 
The first hypothesis, that there would be a significant condition by time interaction on 
change of academic expectancies and consumption and that participants in the EC and PE 
conditions would demonstrate similar reductions through 1-month follow-up but only 
participants in the EC condition would maintain these effects, was only partially supported. 
Results from the HLM analysis examining change in academic expectancies found a significant 
main effect of time but no statistically significant effect of condition when only the EC and PE 
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conditions were included in the model. In this regard, participants in both “treatment” conditions 
demonstrated a similar rate of decline for academic expectancies at 1-month after receiving the 
study intervention; however there was no differential rate of change for expectancies between the 
EC and PE conditions at the 3-month follow-up time point as originally anticipated. Results from 
the HLM analyses examining change in consumption were identical to those for academic 
expectancies.  
Though participants in both treatment conditions experienced a significant reduction in 
expectancies and consumption, results from the two treatment conditions did not significantly 
differ as anticipated. There are a few possible reasons for this finding. First, results from the 
manipulation check indicate that a majority of participants in the EC condition did not feel more 
awake, more jittery, more alert, experience an increased heartbeat, or experience an improved 
mood (i.e., feel happier) as a result of taking the placebo. Similarly, results from the Effects of 
Medication questionnaire which was used to measure the extent to which participants believed 
that the medication affected them physically and cognitively, revealed a below-average score (M 
= 24.22, SD = 13.24; scale mean = 38), suggesting that the placebo manipulation was not 
effective. Overall, a large minority of the EC participants (n=11, 42.3%) believed that their 
performance on the second set of cognitive tests remained the same after taking the supposed 
methylphenidate. Anecdotally, many of these participants attributed their perceived lack of 
change in their performance to not having taken enough medication to help them perform better. 
Similarly, during the debriefing portion of the study, most of the participants reported that they 
believed they were not given enough of the medication to experience such side effects rather 
than believing they were not administered legitimate Ritalin® medication at all. In the end, the 
expectancy challenge paradigm may not have been as potent as anticipated due to students’ 
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thinking that they were not given enough of the medication to affect their cognitive performance. 
Consequently, their beliefs about the medication were not adequately challenged, resulting in a 
less significant decline in expectancies and consumption than hypothesized.  
A second reason why there may not have been a significant difference between the EC 
and PE conditions is because the two conditions had much in common. The primary way in 
which the two conditions differed was that the EC condition contained the experiential 
component of directly challenging the participants’ beliefs about stimulant medication though 
use of a placebo pill, where the PE condition only delivered education with regards to 
Expectancy Theory as it applies to stimulant medications and education about the drug. 
However, the EC condition also contained this same educational component. Therefore, given 
that the experimental aspect of the expectancy challenge did not succeed, the EC condition may 
have mimicked the PE condition, resulting in non-significant group differences.    
The second hypothesis, that change in academic expectancies from baseline to 1-month 
follow-up would mediate the relationship between condition and consumption at 3-month 
follow-up, was not supported. This was due to the fact that one of the conditions required to infer 
the presence of mediation, a significant relationship between the mediating variable (i.e., change 
in academic expectancies) and the dependent variable (i.e., consumption at 3-month follow-up), 
was not met. Although there was a significant treatment-related effect on consumption at 3-
month follow-up (c-path) and change in academic expectancies at 1-month follow-up (a-path), it 
does not appear that expectancies mediated consumption. Low variability due to a restricted 
range for the consumption variable, as well as zero-inflated data for the consumption variable, 
may have led to this outcome. A restricted range and a high incidence of zeros in a data set 
substantially affect the correlation between two variables such that the strength of a relationship 
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between the variables may not be of the magnitude expected, or a relationship may not be 
defined at all. Pertaining to the data obtained in this study, as depicted in Figure 4, the variability 
in consumption was low, with the mean number of days of consumption at each follow-up 
assessment point at 1.2, and the range was from 0 to 3 days, with a majority of the data points at 
each follow-up assessment point being zero. Consequently, the correlation between change in 
academic expectancies and consumption was non-significant. Further, expectancies related to 
non-prescribed use of stimulant medications may be similar to alcohol expectancies in that they 
may be more strongly associated with quantity of consumption rather than frequency of 
consumption. Though attempts were made to assess for quantity consumed in this study, a 
reliable variable could not be calculated, and frequency of use was utilized instead. This may 
have led to a weak relationship between changes in academic expectancies and consumption, 
thus affecting finding a significant relationship between the mediator and outcome variables. 
Finally, another possibility for a lack of a significant mediation finding may be due to the lack of 
a systematic relationship between academic expectancies and consumption of stimulant 
medications.  
There were problems with both recruitment and sample attrition that are important to 
discuss. Recruitment proved to be much more of a challenge than anticipated. As stated 
previously, based on prior stimulant medication research conducted with undergraduate Syracuse 
University students (Labbe & Maisto, 2010), it was anticipated that, over the course of 45 weeks, 
approximately 458 students would inquire about the study, and 215 would enroll, resulting in 5 
students enrolling each week. A few reasons for the large discrepancy in projections and actual 
recruitment can be considered.  
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First, students may not have felt comfortable calling or emailing to participate in a 
research study about their use of stimulant medications. Although the recruitment flyers and 
advertisements did not state that the research team was looking for people who used the 
medication in a non-prescribed manner, students still might have felt uncomfortable self-
selecting into a study with an explicit focus on this topic. Second, the time commitment may 
have been a deterrent. All recruitment materials stated that the study consisted of participating in 
two in-person sessions and three telephone follow-up calls. For many, this time commitment 
might have been perceived as a burden, resulting in fewer study inquiries and participants 
enrolled. Study demands might have also been perceived as too burdensome. The recruitment 
materials stated that participants would “complete questionnaires and some short tests.” For 
some students, this might have been viewed as too much work that was not worth the effort or 
potential financial reimbursement, thus leading to fewer inquiries and subjects enrolled. Finally, 
lack of an explicit statement regarding how much participants would be reimbursed may have 
affected recruitment rates. Perhaps for some students, this information might have been the 
decision-point upon which they chose to inquire about the study or not. It might have been 
helpful to state how much each participate could earn, however this was not permitted by the 
Syracuse University Institutional Review Board as it can be perceived as coercive.  
Attrition was another considerable problem in this study. As stated previously, attrition 
rates ranged from 41.0% at post-test to 61.5% at three-month follow-up. Although there were no 
significant differences across conditions with regards to attrition, non-completers had a greater 
average number of days of non-prescribed use of stimulant medications at baseline compared to 
study completers (14.23 versus 4.96 days, respectively; p = 0.01). Previous research has shown 
that heavier use is associated with more strongly held positive expectancies about a drug 
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(Rohsenow, 1983; Stacy et al., 1990; Schafer & Brown, 1991; Engels & ter Bogt, 2004; Aarons, 
Brown, Stice, & Coe, 2001; Hayaki, Anderson, & Stein, 2008), thus making them more difficult 
to modify. Pertaining to the sample in this study, non-completers used more heavily, suggesting 
these students had more strongly held positive beliefs about the effects of stimulant medication 
related to academic performance. As such, these participants may not have agreed with or 
believed the information they were given regarding their potentially inaccurate beliefs or the 
negative consequences that can be sustained from continued and excessive non-prescribed use. 
As a result, these individuals may not have felt compelled or motivated to remain in the study. 
According to proponents of self-perception theory, the more one argues on behalf of a particular 
position, the more committed he or she becomes to that position, regardless of how accurate it is 
(Bem, 1967). Accordingly, perhaps the more students were challenged about their beliefs and 
told that their misuse of stimulant medications was unhealthy, the more they held onto their pre-
existing beliefs that there was nothing wrong with their behaviors. Consequently, this may have 
caused a substantial portion of the participants to drop out of the study. Another possible reason 
for the high attrition rates may have been related to financial incentives. For the in-person 
sessions, participants were either paid $20 to complete both in-person sessions or received two 
credits for completing the in-person sessions if they were research subject pool participants. All 
participants were paid $15 for the post-test and 1-month follow-up sessions, and $20 for the 3-
month follow-up session. In total, participants earned either two credits plus $50, or $70. A 
majority of the research participants were self-selected from the psychology research subject 
pool. Especially for these students, once they received their study credits they might not have 
had additional motivations to continue with the project, thus dropping out of the study early on. 
For others, the amount of money they were receiving for completing the follow-up calls might 
   
  46 
  
not have been incentivizing enough to complete the protocol. Also, reimbursement, except for 
the in-person sessions, was in the form of Amazon.com gift cards. Some participants might have 
disliked the gift cards, or might have had no use for the gift cards, and preferred a cash payment. 
Therefore, they might have felt that participation was not worth their effort. Finally, loss of 
interest in the project might have led to elevated attrition rates. The study consisted of five 
meetings in total. Generally, a majority of the attrition occurred after the in-person sessions. As 
the distance from the in-person sessions increased, participants may have lost interest in the 
study and, as a consequence, chose not, or continually forgot, to return follow-up calls. The best 
evidence for this potential reason can be seen from the participant tracking spreadsheet kept for 
the study. Every contact with each participant was documented. Most participants were 
contacted, both via email or telephone, at least three times and at various times of day and 
various days of the week. Participants were provided with a study email address and phone 
number so that they could contact study staff using whichever method suited them best. In the 
end, despite these efforts, the presumption was that students grew disinterested and chose not to 
complete the study. 
Limitations 
 This study has some limitations that need to be considered. The first limitation pertains to 
the external validity of the study. Because only Syracuse University undergraduate students 
participated in this study, findings from this study cannot be generalized to other undergraduate 
students in other geographic areas of the U.S. who engage in non-prescribed use of stimulant 
medication. Additionally, students volunteered to participate in this study. It may be the case that 
these students are somehow different than students who engage in non-prescribed use of 
stimulant medications but chose not to participate. For example, it is not possible to know if the 
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students who self-selected into the study tended to consume more or less medication, or had 
more strongly held positive expectancies about the medication, than students who did not 
participate in the study. Consequently, because of the potential differences between those who 
choose to participate in the research versus those who do not, the generalizability of the results of 
this study is accordingly limited. 
 A second limitation of the study is related to a measurement issue for the primary 
outcome variable of consumption. This variable of interest was assessed via a valid and reliable 
self-report measure. Though previous research on the Time-Line Follow-Back interview has 
shown agreement with collateral reports of patients’ substance use, as well as with patient urine 
assays (Fals-Stewart et al., 2000), there is still the potential for participants to under-estimate 
their use of the medication, either because of poor recall of their use or because of social 
desirability (i.e., recognizing that they may not be viewed favorably if they admit to frequently or 
heavily engaging in non-prescribed use of a drug). Such potential under-reporting may explain 
the high incidence of zeros in the distribution of the consumption variable which, as stated 
previously, may have affected the ability to detect a mediating effect between change in 
expectancies and consumption.  
Another measurement limitation occurred with regards to the calculation of the 
consumption variable. The consumption variable for this study was based on frequency (i.e., 
number of days stimulant medication was consumed) rather than based on quantity (i.e., number 
of pills taken or dosage taken). Research has shown that expectancies are more strongly 
associated with quantity of drug or alcohol consumed than with frequency of consumption 
(Chen, Grube, & Madden, 1994; McMahon, Jones, & O’Donnell, 1994; Mooney, Fromme, 
Kivlahan, & Marlatt, 1987). As mentioned earlier, though attempts were made to collect data 
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from participants regarding quantity consumed (i.e., number of pills, dosage), due to 
heterogeneity of type of medication used and participants’ lack of knowledge regarding dosage 
or number of pills consumed, a reliable quantity variable could not be calculated. As an 
alternative, a frequency variable was created to examine effects of the intervention on 
consumption. Had a more reliable and accurate consumption variable based on quantity been 
able to be created, this may have led to different results in the analyses, particularly with regards 
to the test of mediation. 
Yet another measurement issue that may have affected study results was the data analytic 
approach used to test for mediation. Repeated measures multilevel mediation analysis in HLM 
has no gold standard approach. HLM predicts slopes based on existing data in an effort to model 
trajectories of change. Unfortunately, HLM is unable to predict the slope for one variable based 
on the slope of another variable, which was the case in testing the relationship between the 
mediating variable and the dependent variable (b-path). As stated previously, to account for this 
problem, a change score was calculated for academic expectancies which was utilized as a proxy 
in order to test the relationship between the mediating variable and the dependent variable. This 
shortcoming may have affected the results of the mediation analysis, leading to the conclusion of 
no evidence for mediation as predicted. 
A small sample size and significant attrition present additional limitations to the study’s 
findings. First, due to recruitment difficulties, the sample size was small, leading to an under-
powered mediation analysis. As stated previously, approximately 94 subjects would have been 
needed to detect a medium mediated effect (0.3) with power = 0.8. Therefore, the ability to 
detect a significant mediated effect may have been affected due to the smaller sample size. 
Second, due to attrition, there was a substantial amount of missing data. One of the benefits of 
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HLM is that it accommodates for missing data and estimates population parameters by using an 
iterative method based on existing data. Therefore, observations were not dropped from the 
analyses and power was not further reduced. However, estimated data to calculate population 
parameters might result in slightly different results than having more complete actual observed 
data for population estimates. Consequently, missing data may have affected the overall study 
findings.  
Finally, an insufficient placebo manipulation limits the interpretability of the study’s 
findings. The placebo manipulation did not work as well as intended, which appeared to 
significantly affect the potency of the expectancy challenge. The only difference between the 
expectancy challenge condition and psychoeducation condition was the experiential aspect of the 
intervention meant to explicitly challenge students’ beliefs about the effects of stimulant 
medications. Without this component, the two conditions were the same. Accordingly, because 
the experiential aspect of the intervention was ineffective, it did not produce the expected effects. 
Consequently, without the manipulation, the expectancy challenge condition and the 
psychoeducation condition appeared to be more similar than different, resulting in non-
significant differences between the conditions as hypothesized.   
Directions for Future Research 
 Results from this study stimulate several suggestions for future research. Given the 
number of limitations identified, it is important to correct them and then replicate the study to see 
if the initial predictions are borne out. Two main suggestions are offered with regards to 
addressing the primary limitations of the study. First is to address the problem related to the 
placebo manipulation. Given that a majority of the participants in the Expectancy Challenge 
condition stated that they did not believe they were given enough medication to affect their 
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cognitive performance, which might have led to non-significant group differences between the 
EC condition and PE condition, future research should enhance the EC placebo manipulation. If 
participants are asked what kind of medication they normally take and how much, and the same 
“medication” with the same dosage was provided, then perhaps this might mitigate any doubts 
participants had about the placebo and increase the effectiveness/potency of the expectancy 
challenge. Second is to address the problems related to creating a consumption variable based on 
quantity rather than frequency of use. Several possible strategies can be employed to help 
increase the accuracy of this variable. To begin, all participants can be asked to locate the name 
and dosage of the medication they typically take before they come in for their initial baseline 
session. As a result, this information can be applied when completing the TLFB interview. For 
students who cannot locate this information, a descriptive page with colored pictures of the 
various types of stimulant medications can be presented for participants to review. They can then 
indicate which medications they took while completing the TLFB interview. Last, with the help 
of a physician familiar with prescribing stimulant medications, a conversion chart can be created 
that compares the dosage of each medication relative to each other. For example, 30mg of 
Adderall is equivalent to 20mg of Ritalin. In this regard, after data are collected from the TLFB 
interview, dosages from the various medications can be converted into a similar “metric”, thus 
allowing for a more accurate quantity variable that can be utilized for the analyses.    
Another area for future research is to employ and test the efficacy of the expectancy 
challenge during certain times of the academic school year when non-prescribed use of stimulant 
medications is most common (i.e., mid-terms and finals). This study recruited students over the 
course of the entire school year, perhaps contributing to the widely varying rates of consumption. 
It would be of interest to learn if the intervention was efficacious in reducing expectancies and/or 
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consumption when administered immediately prior to periods of high rates of consumption. If 
use is most problematic during these times, perhaps it would be more reasonable and more 
pertinent to target reduction of use during these times, rather than more globally throughout the 
year. In the current study, it may have been the case that students were consuming the 
medication at a rate that was not particularly concerning to them (i.e., one pill every couple of 
weeks). As a result, their motivation to modify their beliefs about the effects of the medication 
and/or their consumption may have been low. However, students may be more motivated to 
change their beliefs and behaviors during a time when they are using the drug on a more 
consistent basis, or in higher doses, such as during mid-terms or finals, when they learn that their 
beliefs are inaccurate and that heavy use can incur harm. The tenets of the intervention may be 
more salient to students at these times, leading to increased motivation to process information 
and change beliefs and behaviors that might not be present during other times of the academic 
year. 
Given that participants in the psychoeducation condition exhibited a statistically 
significant decrease in academic expectancies and consumption, future research ought to 
systematically study the educational component of the psychoeducation condition as a viable 
option to both prevent students from engaging in non-prescribed use of stimulant medications, 
and to intervene after use has begun to promote reduction or discontinuation of use. If proven to 
be efficacious, this may be a feasible and cost effective approach that can be easily disseminated 
across college campuses, such as becoming part of new student orientation material, or utilized 
as a brief intervention administered in either a medical or mental health setting. Further, 
considering the high rates of non-prescribed use of stimulant medications among high school 
students (annual prevalence rates ranged from 4.6% to 6.5%; Johnston et al., 2012), if systematic 
   
  52 
  
study of the didactic component proves that this information substantially reduces consumption, 
then presenting this information in high school health classes may be an efficient and effective 
way to curtail non-prescribed use of stimulant medications in adolescents, and potentially serve 
as a protective factor against initiation of use for those student continuing on to college. 
General Summary and Conclusions 
As a result of the increasing competitiveness of the college environment, a significant 
proportion of college students have turned to non-prescribed use of stimulant medications as a 
way to boost their academic performance. Unfortunately, there is no evidence supporting 
students’ beliefs that stimulant medications can actually improve one’s cognitive or academic 
functioning. However, a majority of these students are unaware of this fact and believe that, 
because the medication helps individuals with ADHD, it will benefit them in the same manner. 
More importantly, these students are naïve to the kind of medication they are misusing (i.e., a 
controlled substance belonging to the same drug class as cocaine) and to the serious and negative 
side effects and consequences that can occur from excessive, long-term use. The purpose of this 
study was to develop and test the efficacy of an intervention aimed to challenge students’ beliefs 
about stimulant medications, with the ultimate goal of reducing and eliminating consumption. 
The overall results of the study indicate that students’ expectancies related to academic 
performance, as well as consumption, were reduced, however these findings may be a result of 
the didactic component of the intervention. As noted, additional work needs to be conducted to 
strengthen the potency of the expectancy challenge condition to draw clear conclusions about its 
effectiveness. Regardless, the general conclusion from this study is that expectancies related to 
non-prescribed use of stimulant medication and consumption of the drug are modifiable, and that 
this effect can be maintained over time.  
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Table 1. Schedule of measures. 
 
Measures 
Baseline/ 
1st Testing 
Session 
2nd 
Testing 
Session 
Post-
Treatment 
1-month 
follow-up
3-month 
follow-
up 
Demographics 
Survey 
X     
Substance Use TLFB X  X X X 
SMOEQ X  X X X 
Effects of medication 
questionnaire  
(EC only) 
 X    
Digit Span subtest X X    
Letter-Number 
Sequencing subtest 
X X    
Note: Two weeks occurs between baseline/first testing session and the second testing session, 
and one week occurs between the second testing session and the post-treatment session.
  64   
Table 2. Baseline descriptive statistics.  
 Total Sample Condition 
 (N=78) AO (N=31) PE (N=21) EC (N=26) 
 M (SD) N (%) M (SD) N (%) M (SD) N (%) M (SD) N (%) 
Age 19.5 (1.39) -- 19.7 (0.25) -- 19.47 (0.35) -- 19.58 (0.28) -- 
GPA 3.1 (0.50) -- 3.18 (0.07) -- 3.25 (0.07) -- 2.96 (0.13) -- 
Sex 
   Male 
 
-- 
 
41 (52.6)
 
-- 
 
14 (45.2) 
 
-- 
 
10 (47.6) 
 
-- 
 
17 (65.4) 
Race 
   Caucasian 
   Asian 
   African American 
   Other 
 
-- 
-- 
-- 
-- 
 
52 (66.7) 
11 (14.1) 
8 (10.3) 
7 (9.0) 
 
-- 
-- 
-- 
-- 
 
20 (64.5) 
6 (19.4) 
4 (12.9) 
1 (3.2) 
 
-- 
-- 
-- 
-- 
 
14 (66.7) 
4 (19.0) 
1 (4.8) 
2 (9.5) 
 
-- 
-- 
-- 
-- 
 
18 (69.2) 
1 (3.8) 
3 (11.5) 
4 (15.4) 
Ethnicity 
   Not Hispanic/Latino 
 
-- 
 
70 (89.7)
 
-- 
 
28 (90.3) 
 
-- 
 
18 (85.7) 
 
-- 
 
24 (92.3) 
Year in School 
   Freshman 
   Sophomore 
   Junior 
   Senior 
 
-- 
-- 
-- 
-- 
 
26 (33.3) 
26 (33.3) 
13 (16.7) 
13 (16.7)
 
-- 
-- 
-- 
-- 
 
9 (29.0) 
12 (38.7) 
5 (16.1) 
5 (16.1) 
 
-- 
-- 
-- 
-- 
 
9 (42.9) 
6 (28.6) 
4 (19.0) 
2 (9.5) 
 
-- 
-- 
-- 
-- 
 
8 (30.8) 
8 (30.8) 
4 (15.4) 
6 (23.1) 
Greek Membership 
   Not a member 
   Fraternity 
   Sorority 
 
-- 
-- 
-- 
 
54 (69.2) 
17 (21.8) 
6 (7.7) 
 
-- 
-- 
-- 
 
19 (61.3) 
7 (22.6) 
5 (16.1) 
 
-- 
-- 
-- 
 
17 (81.0) 
3 (14.3) 
0 (0.0) 
 
-- 
-- 
-- 
 
18 (69.2) 
7 (26.9) 
1 (3.8) 
Method of Consumption 
   Oral 
   Nasal 
   Both 
 
-- 
-- 
-- 
 
60 (76.9) 
1 (1.3) 
13 (16.7)
 
-- 
-- 
-- 
\ 
24 (77.4) 
0 (0.0) 
6 (19.4) 
 
-- 
-- 
-- 
 
15 (71.4) 
0 (0.0) 
4 (19.0) 
 
-- 
-- 
-- 
 
21 (80.8) 
1 (3.8) 
4 (15.3) 
Own a Prescription? 
   No 
 
-- 
 
62 (79.5)
 
-- 
 
27 (87.1) 
 
-- 
 
17 (81.0) 
 
-- 
 
18 (69.2) 
SMOEQ 
   Total scale score 
   Academic expectancies score 
 
86.7 (10.08) 
46.05 (6.36) 
 
-- 
-- 
 
86.53 (2.54) 
46.33 (1.53) 
 
-- 
-- 
 
88.58 (1.49) 
46.95 (1.02) 
 
-- 
-- 
 
86.5 (1.42) 
45.75 (0.92) 
 
-- 
-- 
Substance Use TLFB 
   Total days stimulant medication used 
   Total alcoholic drinks consumed 
   Total days alcohol consumed 
   Total days marijuana consumed 
   Total numbers of cigarettes smoked 
 
10.7 (16.19) 
166.6 (148.82) 
25.7 (16.57) 
30.3 (33.16 
127.4 (255.19) 
 
-- 
-- 
-- 
-- 
-- 
 
7.87 (2.41) 
156.61 (29.02) 
22.6 (2.89) 
36.37 (6.67) 
106.43 (40.22) 
 
-- 
-- 
-- 
-- 
-- 
 
9.58 (2.81) 
135.71 (30.43) 
31.79 (3.57) 
37.0 (8.03) 
169.21 (67.92) 
 
-- 
-- 
-- 
-- 
-- 
 
13.5 (3.64) 
185.36 (30.08) 
26.0 (3.69) 
17.83 (4.9) 
146.92 (58.56) 
 
-- 
-- 
-- 
-- 
-- 
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Table 3. Means, standard deviations, and inter-correlations of study variables. 
 Demographics Academic Expectancies Consumption 
 GPA MJ use days BL Post 1mo 3mo BL Post 1mo 3mo 
3.10 30.26 47.04 44.74 42.60 41.40 5.62 1.15 1.15 1.20 Mean 
(SD) (0.50) (33.16) (3.13) (3.93) (3.99) (3.74) (3.19) (1.25) (1.28) (1.71) 
GPA  1.0 -- -- -- -- -- -- -- -- -- 
MJ use days  .001 1.0 -- -- -- -- -- -- -- -- 
Academic BL -.03 .27* 1.0 -- -- -- -- -- -- -- 
Expectancies Post -.23 .07 .33* 1.0 -- -- -- -- -- -- 
 1mo -.17 .14 .43** .75** 1.0 -- -- -- -- -- 
  3mo -.28 .08 .29 .73** .60** 1.0 -- -- -- -- 
Consumption BL -.12 .12 .13 -.25 -.13 -.18 1.0 -- -- -- 
 Post -.03 -.11 -.12 -.18 .03 .10 .50** 1.0 -- -- 
 1mo .11 -.08 .09 .10 .17 .43* .44** .67** 1.0 --  
 3mo -.11 .17 .15 .23 .09 .22 .12 .31 .33 1.0 
Note. Means and standard deviations based on Winsorized values. * p < .05, ** p < .01 
 
   
  66   
Table 4. Test-retest reliability statistics for the SMOEQ. 
 ICC (95% C.I.) 
Total SMOEQ 
   Baseline to Post-Test 
   Post-Test to 1-Month Follow-Up 
   1-Month Follow-Up to 3-Month Follow-Up 
   Baseline to 3-Month Follow-Up 
 
0.82 (0.56 – 0.93) 
0.76 (0.28 – 0.92) 
0.75 (0.12 – 0.93) 
0.65 (-0.10 – 0.89) 
Academic Subscale of SMOEQ 
   Baseline to Post-Test 
   Post-Test to 1-Month Follow-Up 
   1-Month Follow-Up to 3-Month Follow-Up 
   Baseline to 3-Month Follow-Up 
 
0.87 (0.70 – 0.95) 
0.88 (0.65 – 0.96) 
0.91 (0.70 – 0.98) 
0.70 (0.05 – 0.90) 
Note. ICC = Intraclass correlation coefficient; SMOEQ = Stimulant Medication Outcome 
Expectancy Questionnaire. ICC calculated using the “mixed model, type consistency, 
averaged measures” option in SPSS with data from participants in the Assessment-Only 
condition. 
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Table 5. Cognitive test scores. 
 1st Test Session 
M (SD) 
2nd Test Session 
M (SD) 
Assessment Only Condition 
   Digit Span Total Score 
   Letter-Number Sequencing 
 
17.67 (0.74) 
11.52 (0.50) 
 
18.22 (0.60) 
12.67 (0.54) 
Psychoeducation Condition 
   Digit Span Total Score 
   Letter-Number Sequencing 
 
18.35 (0.94) 
11.35 (0.90) 
 
19.85 (1.01) 
13.20 (0.81) 
Expectancy Challenge Condition   
   Digit Span Total Score 
   Letter-Number Sequencing 
 
18.32 (0.83) 
12.47 (0.74) 
 
19.16 (0.88) 
12.79 (0.79) 
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Table 6. HLM models including coefficients and significance tests for level-1 and level-2 
for academic expectancies 
Level-1 Coefficient Standard Error t Ratio df P 
Fixed effects 
   Expectancies intercept 
       Average initial expectancies 
   Expectancies slope (per week) 
       Average slope 
 
 
 
46.40 
 
-0.39 
 
 
0.34 
 
0.04 
 
 
137.60 
 
-9.97 
 
 
77 
 
77 
 
 
<0.001 
 
<0.001 
Random effects SD Variance χ2 df p 
   Intercept 
   Slope 
   Error 
 
2.02 
0.08 
2.74 
4.09 
0.007 
7.51 
92.26 
46.82 
54 
54 
0.001 
>0.50 
Level-2 (all three conditions) Coefficient Standard Error t Ratio df p 
Fixed effects 
   Average slope (per week) 
       Expectancies slope 
       Condition slope 
       GPA slope 
       Marijuana use slope 
    
 
 
-0.30 
-0.10 
-0.08 
-0.0004 
 
 
0.05 
0.05 
0.10 
0.001 
 
 
-5.62 
-2.08 
-0.85 
-0.29 
 
 
74 
74 
74 
74 
 
 
<0.001 
0.04 
0.39 
0.77 
Random effects SD Variance χ2 df p 
   Intercept 
   Slope 
   Error 
 
1.97 
0.06 
2.78 
3.87 
0.004 
7.75 
89.40 
45.02 
54 
51 
0.002 
>0.50 
Level-2 (PE vs. EC) Coefficient Standard Error t Ratio df p 
Fixed effects 
   Average slope (per week) 
       Expectancies slope 
       Condition slope 
       GPA slope 
       Marijuana use slope 
 
 
 
-0.55 
0.19 
-0.14 
0.002 
 
 
 
0.06 
0.10 
0.06 
0.002 
 
 
-8.94 
1.97 
-2.23 
1.41 
 
 
43 
43 
43 
43 
 
 
 
<0.001 
0.055 
0.03 
0.17 
Random effects SD Variance χ2 df p 
   Intercept 
   Slope 
   Error 
 
1.14 
0.02 
3.18 
1.29 
0.0003 
10.12 
25.43 
17.33 
28 
25 
>0.50 
>0.50 
Level-2 (AO vs. PE+EC) Coefficient Standard Error t Ratio df p 
Fixed effects 
   Average slope (per week) 
       Expectancies slope 
       Condition slope 
 
 
 
-0.25 
-0.25 
 
 
 
0.05 
0.07 
 
 
-4.70 
-3.64 
 
 
76 
76 
 
 
<0.001 
<0.001 
Random effects SD Variance χ2 df p 
   Intercept 
   Slope 
   Error 
1.99 
0.03 
2.76 
3.95 
0.001 
7.62 
90.84 
44.37 
54 
53 
0.002 
>0.50 
Note.  All analyses based on Winsorized values for academic expectancies. 
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Table 7. HLM models including coefficients and significance tests for level-1 and level-2 
for stimulant medication consumption. 
Level-1 Coefficient Standard Error t Ratio df p 
Fixed effects 
   Consumption intercept 
       Average initial consumption 
   Consumption slope (per week) 
       Average slope 
 
 
 
4.27 
 
-0.32 
 
 
0.31 
 
0.04 
 
 
13.98 
 
-8.71 
 
 
77 
 
77 
 
 
<0.001 
 
<0.001 
Random effects SD Variance χ2 df p 
   Intercept 
   Slope 
   Error 
 
1.87 
0.19 
2.37 
3.49 
0.04 
5.60 
103.09 
72.43 
53 
53 
<0.001 
0.04 
Level-2 (all three conditions) Coefficient Standard Error t Ratio df p 
Fixed effects 
   Average slope (per week) 
       Consumption slope 
       Condition slope 
       GPA slope 
       Marijuana use slope 
    
 
 
-0.29 
-0.04 
0.06 
-0.00006 
 
 
0.05 
0.03 
0.04 
0.0007 
 
 
-6.39 
-1.61 
1.55 
-0.08 
 
 
74 
74 
74 
74 
 
 
<0.001 
0.11 
0.13 
0.94 
Random effects SD Variance χ2 df p 
   Intercept 
   Slope 
   Error 
 
1.90 
0.20 
2.36 
3.61 
0.04 
5.57 
103.79 
72.41 
53 
50 
<0.001 
0.02 
Level-2 (PE vs. EC) Coefficient Standard Error t Ratio df p 
Fixed effects 
   Average slope (per week) 
       Consumption slope 
       Condition slope 
       GPA slope 
       Marijuana use slope 
 
 
 
-0.68 
0.06 
0.06 
0.002 
 
 
0.14 
0.04 
0.03 
0.001 
 
 
-4.93 
1.75 
1.60 
2.04 
 
 
43 
43 
43 
43 
 
 
<0.001 
0.09 
0.12 
0.05 
Random effects SD Variance χ2 df p 
   Intercept 
   Slope 
   Error 
 
2.28 
0.24 
2.35 
5.21 
0.06 
5.53 
66.52 
45.02 
28 
25 
<0.001 
0.01 
Level-2 (AO vs. PE+EC) Coefficient Standard Error t Ratio df p 
Fixed effects 
   Average slope (per week) 
       Consumption slope 
       Condition slope 
 
 
 
-0.28 
-0.08 
 
 
0.04 
0.04 
 
 
-6.30 
-2.07 
 
 
76 
76 
 
 
<0.001 
0.04 
Random effects SD Variance χ2 df p 
   Intercept 
   Slope 
   Error 
1.89 
0.19 
2.35 
3.58 
0.04 
5.53 
104.58 
71.57 
53 
52 
<0.001 
0.04 
Note.  All analyses based on Winsorized values for stimulant medication consumption.  
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Table 8. Mediation analysis. 
Level-1 (Consumption) Coefficient Standard Error t Ratio df p 
Fixed effects 
   Consumption intercept 
       Average initial consumption 
   Consumption slope (per week) 
       Average slope 
 
 
4.27 
 
-0.32 
 
 
0.31 
 
0.04 
 
 
13.98 
 
-8.71 
 
 
77 
 
77 
 
 
<0.001 
 
<0.001 
Random effects SD Variance χ2 df p 
   Intercept 
   Slope 
   Error 
1.87 
0.19 
2.37 
3.49 
0.04 
5.60 
103.09 
72.43 
53 
53 
<0.001 
0.04 
Level-1 (Academic expectancies) Coefficient Standard Error t Ratio df p 
Fixed effects 
   Expectancies intercept 
       Average initial expectancies 
   Expectancies slope (per week) 
       Average slope 
 
 
46.23 
 
-0.69 
 
 
0.33 
 
0.08 
 
 
138.40 
 
-8.79 
 
 
77 
 
77 
 
 
<0.001 
 
<0.001 
Random effects SD Variance χ2 df p 
   Intercept 
   Slope 
   Error 
1.86 
0.23 
2.51 
3.46 
0.05 
6.31 
88.46 
60.64 
53 
53 
0.002 
0.22 
Level-2 (c-path) Coefficient Standard Error t Ratio df p 
Fixed effects – Average slope (per 
week) 
       Consumption slope 
       Condition slope 
 
-0.28 
-0.08 
 
0.04 
0.04 
 
-6.30 
-2.07 
 
76 
76 
 
<0.001 
0.04 
Random effects SD Variance χ2 df p 
   Intercept 
   Slope 
   Error 
1.89 
0.19 
2.35 
3.58 
0.04 
2.53 
104.58 
71.57 
53 
52 
<0.001 
0.04 
Level-2 (a-path) Coefficient Standard Error t Ratio df p 
Fixed effects – Average slope (per 
week) 
       Expectancies slope 
       Condition slope 
 
-0.47 
-0.40 
 
0.10 
0.14 
 
-4.84 
-2.79 
 
76 
76 
 
<0.001 
0.01 
Random effects SD Variance χ2 df p 
   Intercept 
   Slope 
   Error 
1.82 
0.19 
2.54 
3.30 
0.04 
6.43 
86.85 
57.16 
53 
52 
0.003 
0.29 
Level-2 (b-path) Coefficient Standard Error t Ratio df p 
Fixed effects - Average slope (per 
week) 
       Consumption slope 
       Change in expectancies slope 
 
-0.32 
0.0003 
 
0.04 
0.004 
 
-8.76 
0.98 
 
76 
76 
 
<0.001 
0.92 
Random effects SD Variance χ2 df p 
   Intercept 
   Slope 
   Error 
1.86 
0.19 
2.38 
3.46 
0.04 
5.65 
102.30 
71.95 
53 
52 
<0.001 
0.04 
Level-2 (c’-path) Coefficient Standard Error t Ratio df p 
Fixed effects - Average slope (per 
week) 
       Consumption slope 
       Condition slope 
       Change in expectancies slope 
 
-0.26 
-0.08 
0.002 
 
0.04 
0.04 
0.004 
 
-6.31 
-2.13 
0.44 
 
75 
75 
75 
 
<0.001 
0.04 
0.66 
Random effects SD Variance χ2 df p 
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   Intercept 
   Slope 
   Error 
1.89 
0.19 
2.36 
3.56 
0.04 
5.56 
103.85 
71.30 
53 
51 
<0.001 
0.03 
Note. Effects for academic expectancies based on data from baseline through 1-month follow-up.
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Figure 1. Conceptual model of mediation. 
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Figure 2. Participant Flowchart. 
81 Subjects were enrolled and completed 
baseline measures 
78 Subjects Randomized 
Post-Test Assessment 
23 Completed 
  8 Were not retained/ 
     unable to contact 
Post-Test Assessment 
12 Completed 
  9 Were not retained/ 
     unable to contact 
Post-Test Assessment 
11 Completed 
  15 Were not retained/ 
     unable to contact 
1-Month Assessment 
19 Completed 
  4 Were not retained/ 
     unable to contact 
1-Month Assessment 
12 Completed 
  0 Were not retained/ 
     unable to contact 
1-Month Assessment 
12 Completed 
  1 Returned after    
     missing post-test 
3-Month Assessment 
14 Completed 
  5 Were not retained/ 
     unable to contact 
3-Month Assessment 
8 Completed 
4 Were not retained/ 
   unable to contact 
3-Month Assessment 
8 Completed 
4 Were not retained/ 
   unable to contact 
26 Randomized to EC 21 Randomized to PE 31 Randomized to AO 
3 Subjects dropped because of 
ineligibility criteria discovered at 
baseline (2=no non-prescribed use; 
1=too old)  
127 Subjects excluded 
    72 Did not meet inclusion criteria 
        64 Did not report non-prescribed use 
        2 Had Bipolar Disorder 
        1 Had Narcolepsy 
        3 Were too old 
        2 Were not SU students 
        1 Was not able to participate in both     
            testing sessions 
    53 Declined to participate          
208 Subjects were screened for eligibility 
Note. AO = Assessment Only condition; PE = Psychoeducation condition; EC = Expectancy 
Challenge condition.  
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Figure 3. Mean academic expectancies over time by condition. 
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Note. Mean scores based on Winsorized values. 
 
 
 
 
 
 
 
Figure 4. Mean stimulant medication consumption over time by condition. 
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Note. Mean consumption based on Winsorized values. 
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Appendix A 
 
Script for Expectancy Challenge (EC) Condition 
 
[Welcome participant back to the research lab] 
 
Today you’ll be given methylphenidate, a generic version of Ritalin, before you start the 
testing session. As a reminder, we are interested in learning about the effects of stimulant 
medications like Ritalin on college students’ testing performance. Also, a physician is 
working with us on this study and has created a chart for us to use to determine the 
correct dosage to give based on your weight. By “correct dosage” I mean a dose high 
enough that the pharmacological properties of the drug should affect your performance 
on the tests I’ll be giving you. 
 
 
Dosing Guidelines 
 
1. “Before I give you the medication, I need to know how much you weigh so I 
know how much medication to give you. Please step on the scale so we can get 
a reading.” 
a. Write down the person’s weight. 
 
2. “Are you currently taking any medications?” 
a. IF YES: what are they? 
 
3. IF PARTICIPANT IS CURRENTLY PRESCRIBED ADHD MEDICATION 
AND/OR ON AN ANTIDEPRESSANT/SSRI/: 
a. Tell the participant, “Based on your weight, I’d normally give you XX 
dosage, but because of the interaction effects that can occur between 
antidepressant medications and stimulant medication I’m doing to 
drop the dosage by 5mg.” 
 
4. Use the dosing table to determine amount of medication to give the 
participant. 
 
WEIGHT DOSE (Ritalin) 
< 100 lbs 
 
20mg 
100 – 130  lbs 
 
25mg 
140 – 150 lbs 
 
30mg 
150 - 180 lbs 
 
35mg 
180 – 200 lbs 
 
40mg 
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200 – 220 lbs 
 
45mg 
> 220 lbs 
 
50mg 
 
 
5. Discuss with the participant the possible discrepancy between the dose he/she 
was given for the study and the dose he/she normally takes. 
a. “I realize that you might take more than the dosage I’m giving you 
right now for this study, however the dosage I’m giving you has been 
shown to affect performance on these kinds of tests even if you don’t 
feel any physical effects. So, just because you don’t feel any effects 
doesn’t mean that it isn’t working.” 
 
6. “Here is some water so you can take the medication. This is a fast-acting 
medication so it should only take about 15 minutes for the medication to be 
absorbed in your bloodstream. I want to make sure that the medication has 
taken effect before we begin the testing so I’d like you to sit and relax for the 
next 15 minutes. Here are some magazines and newspapers you can read to 
pass the time.” 
 
7. After giving the medication to the participant, ask him/her occasionally if 
he/she is experiencing any physical side effects.  
a. If the participant is concerned about any side effects he/she is having, 
explain that they are only temporary and that the medication is short-
acting so they will go away soon. 
 
[After 15 minutes has elapsed] 
 
OK, the medication should be taking effect by now. I’d like you to answer these few 
questions about how you are feeling right now.  
 
[Give participant drug effects questionnaire] 
 
All right – let’s get started with the testing. If you start feeling jittery or shaky during the 
testing from taking the medication please let me know.  
 
[Administer Digit Span and Letter-Number Sequencing subtests] 
 
Now that we’ve finished the testing, I’d like you to complete this questionnaire about 
how you think the medication may have affected your performance on these tests. 
 
[Administer the Effects of Medication questionnaire and score the tests] 
 
 
Debriefing about Medication / Expectancy Lecture / Feedback on Tests 
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Now that you’ve completed the testing, I want to talk a bit about the medication you took 
at the beginning of today’s session. I actually did not give you real medication; I gave 
you a placebo pill instead. It did not have any active drug in it and is essentially a sugar 
pill. I did this because this study is not really examining the effects of Ritalin on students’ 
testing performance, but how your belief of taking the medication can affect your 
performance.  
 
These beliefs are called “expectancies” and, according to the theory, it is believed that 
people engage in a particular behavior at least partly because they believe or expect that 
by doing this behavior a specific desired outcome will occur. For example, you may drink 
alcohol at a party because you think it will make you more outgoing. Or, you might use 
stimulant medications during final exams week because you think it will make you study 
better.  
 
You were eligible for this study because you said you had used the medication in the past 
three months. Tell me a little bit about why you use the medication and what you expect 
when you use it. [Let the participant respond].  
 
Most students who use the medication without a prescription think similar things. They 
think that the medication will help them stay focused on their work, study better and 
longer, be more productive during their work or study time, help them concentrate better, 
and help them not get so distracted. Generally, people think that if they take the 
medication they will get better grades and be more successful in school.  
 
The problem with this is that there is no evidence that shows that people without ADHD 
actually perform better on tests or in school as a result of taking the medication. In fact, 
research specifically studying whether people without ADHD showed improved 
performance when taking stimulant medications found that there is no significant 
improvement. Therefore, although people without ADHD who take the drug believe the 
medication is making them concentrate and study better, this is not likely to be true. What 
is more likely is that the belief that the medication is supposed to improve things like 
concentration, focus, and attention is actually causing people to behave that way and that 
it’s not so much because of the drug itself. 
 
So, although you may notice that you’re better able to sit and focus and study after taking 
the medication, it’s more likely that you’ve been able to do this all along but that you 
engage in the behavior because you believe that the medication is supposed to cause this 
to happen. 
 
Do you have any questions so far? [Let the participant respond.] 
 
A lot of research has been done on the topic of expectancies and has found that people 
have expectancies about the effects alcohol, marijuana, cocaine, ecstasy, and stimulant 
medications. The most common area that this theory has been applied to is alcohol, so 
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let’s review an example with alcohol before we talk about how it applies to drugs like 
Ritalin.  
 
Many people believe that if they drink a lot of alcohol at a party they will become more 
outgoing and sociable. Because people believe that drinking a certain amount of alcohol 
at a party will cause this type of outcome to occur, they intentionally drink this way 
whenever they go out to party and want to achieve this kind of result. However, the 
alcohol is not necessarily making these people be more outgoing and sociable. Instead, 
their expectancies, or beliefs, about what should happen to them when they drink a lot at 
a party seem to cause them to act this way.  
 
Research studies have even found that people who thought they drank an alcoholic mixed 
drink acted more socially, were more talkative, and were more outgoing than people who 
thought they drank a non-alcoholic drink but actually consumed alcohol. This shows that 
expectancies can influence your behavior. In the end, the effects of alcohol (like being 
more sociable), are due to both the pharmacology of alcohol (i.e., being intoxicated) and 
your expectancies of how alcohol will affect you. 
 
Do you have any questions so far? [Let the participant respond.] 
 
Expectancies are important because they are significantly related to how much alcohol or 
drugs you consume. People who have really strong beliefs that positive outcomes will 
occur as a result of drinking alcohol or using drugs are more likely to consume more 
alcohol or drugs than people who don’t have these strong beliefs. Because of this 
association, expectancies can actually predict whether or not you will drink alcohol or use 
drugs in different situations and can predict whether or not you will develop alcohol or 
drug problems.  
 
Because your behavior from drinking alcohol or taking drugs is, in part, because of a 
belief that you hold, becoming aware of these beliefs and being educated about how 
accurate they are can change how strongly you maintain these expectancies. 
Consequently, if your expectancies change, this can also change the amount of alcohol or 
drugs that you consume. For example, if people realize that it’s their belief that is making 
them more outgoing when they drink alcohol at a party and not necessarily because of the 
alcohol itself, then they may no longer feel the need to drink as much whenever they go 
out to party. By changing their expectancies, they also change how much they drink, 
which then reduces risk of serious negative consequences.  
 
Does this make sense to you? [Let the participant respond] 
 
Just as expectancies affect alcohol use, they seem to affect use of prescription stimulant 
medications, like Ritalin and Adderall. 
 
[If the participant endorsed any item as other than 0 on the Effects of Medication 
questionnaire] Let’s take a look at the questionnaire you just filled out about how you 
felt the medication affected you. [Review the items that the participant endorsed.]  
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** PARTICIPANT BELIEVES PERFORMANCE IMPROVED ** 
You indicated that, compared to the first testing session, you felt that your performance 
improved during the second session due to the medication.  
 
So let’s take a look at your actual testing performance. For the Digit Span test, you scored 
a XX the first time, which falls in the [insert corresponding range title] range compared 
to other people your age. You scored a XX the second time, putting you in the [insert 
corresponding range title] range. For the Letter-Number Sequencing test, you scored a 
XX the first time, which falls in the [insert corresponding range title] range compared to 
people your age. You scored a XX the second time, putting you in the [insert 
corresponding range title] range. Do you have any questions about these results? [Let 
the participant respond] 
 
Compared to the first testing session, you actually did [better, worse, the same] during 
the second testing session. So, knowing now that you didn’t actually receive any real 
medication, and considering that you thought your performance improved because of the 
medication, what do you think about these results? [Let the participant respond]    
 
After learning all this and seeing how your expectancies of taking a drug like Ritalin 
affected your performance, what do you think? [Let the participant respond]. Do you 
have any questions before we move on? [Let the participant respond]   
 
** PARTICIPANT BELIEVES PERFORMANCE GOT WORSE ** 
You’ve indicated here that, compared to the first testing session, you felt that you did 
worse. Why do you think this was the case? [Let the participant respond. Based on what 
he/she says, have a discussion about the reasons he/she provides. Possible reasons may 
include: not trying as hard as the first time, boredom, not feeling well. In an extreme 
case, the participant may experience significant physical side effects from taking the 
placebo which may have negatively affected his/her performance.] 
 
OK, so let’s take a look at your actual testing performance. For the Digit Span test, you 
scored a XX the first time, which falls in the [insert corresponding range title] range 
compared to other people your age. You scored a XX the second time, putting you in the 
[insert corresponding range title] range. For the Letter-Number Sequencing test, you 
scored a XX the first time, which falls in the [insert corresponding range title] range 
compared to people your age. You scored a XX the second time, putting you in the 
[insert corresponding range title] range. Do you have any questions about these results? 
[Let the participant respond] 
 
Compared to the first testing session, you actually did [better, worse, the same] during 
the second testing session. What do you think about these results? How do they match 
with how you felt your performance was? [Let the participant respond.] 
 
** PARTICIPANT BELIEVES PERFORMANCE REMAINED THE SAME ** 
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You’ve indicated here that, compared to the first testing session, you felt that you did the 
same – that you didn’t do better or worse. Why do you think this is the case? [Let the 
participant respond. Based on what he/she says, have a discussion about the reasons 
he/she provides. Possible reasons may include: we didn’t give the participant as much 
medication as he/she usually takes, so the medication didn’t affect performance.]   
 
OK, so let’s take a look at your actual testing performance. For the Digit Span test, you 
scored a XX the first time, which falls in the [insert corresponding range title] range 
compared to other people your age. You scored a XX the second time, putting you in the 
[insert corresponding range title] range. For the Letter-Number Sequencing test, you 
scored a XX the first time, which falls in the [insert corresponding range title] range 
compared to people your age. You scored a XX the second time, putting you in the 
[insert corresponding range title] range. Do you have any questions about these results? 
[Let the participant respond] 
 
Compared to the first testing session, you actually did [better, worse, the same] during 
the second testing session. What do you think about these results? How do they match 
with how you felt your performance was? [Let the participant respond.] 
 
Education about Stimulant Medication 
 
The problem is that most people who don’t have ADHD but take the medication anyway 
don’t know about all the side effects that can occur as a result of taking the medication, or 
even know how potent the drug is. Ritalin and Adderall are very strong drugs – so strong 
that they have been labeled as a government-controlled substance, and they belong to the 
same drug category as cocaine. They even affect the brain in the same way that cocaine 
does. Even though Ritalin and Adderall are effective in treating ADHD, they are 
addictive and can cause a variety of serious side effects. Have you ever experienced any 
kind of side effects when you’ve used stimulant medication? [Let the participant 
respond] 
 
At the most basic level, stimulant medications can: 
• increase blood pressure, heart rate, and body temperature 
• decrease sleep and sometimes causes a lack of appetite leading to malnutrition and 
all of its associated problems.  
 
At high dosages these medications can cause serious cardiac problems, such as:  
• an irregular heartbeat  
• rapid heartbeat 
• heart attack 
• stroke  
 
Over the long term, repeated non-prescribed use of the medication can lead to feelings of 
hostility and paranoia.  
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People who chronically misuse the medication can also suffer from withdrawal 
symptoms when they stop using the drug, such as: 
• fatigue 
• depression 
• sleep disturbances 
 
It is also possible to overdose on stimulant medications resulting in symptoms of:  
• nervousness  
• aggression  
• tremor 
• rapid heartbeat  
• personality changes 
• hallucinations 
• delusions 
• sweating 
• vomiting 
• overactive reflexes (causing twitching and spasms)  
 
Rarer overdose symptoms include seizures, kidney damage, and psychosis. 
 
Do you have any questions about this? [Let the participant respond]. 
 
Do you have any concerns about your use of the drug? [Let the participant respond]. 
 
[If the participant has any concerns about his/her drug use or mental health as a result 
of using the drugs, provide him/her with contact information to the Psychological 
Services Center, the Counseling Center, and/or the University Health Services Center.] 
 
[If the participant states that he/she thinks he/she might have ADHD, state that the 
Psychological Services Center offers ADHD assessments and suggest that the 
participant contact them for an assessment if interested. Provide the contact 
information if the participant wants it.] 
 
Scheduling the Post-Test Session 
 
As a reminder, this is a follow-up study, which means I am going to call you to go over 
some brief questionnaires in one week from today, then again one month from today, and 
then one last time three months from today. Also, as a reminder, you will be reimbursed 
for each phone call you complete, earning $15 for next week’s call, and again for the call 
a month from now, and $20 for the final call in three months from now. Reimbursement 
for the phone calls will be with Amazon.com gift cards that will be emailed to you. 
 
Let’s schedule the first phone call now. What time would you prefer I call next week? 
[Fill out a reminder card and give it to the participant].  
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Here are some calendars for the next three months. I’d like you to keep track of when you 
use the stimulant medication and how much you use. When I call you for the follow-up 
sessions I am going to ask you to tell me which days you used the medication and how 
much you used. These calendars will make it easier for you to keep accurate track of this 
information and thus to make the phone calls go much quicker. [Hand participant 
calendars for the next three months]. 
 
Last, here is $10 for completing today’s session. [Give participant the money and then 
have him/her sign a receipt]. 
 
Thanks for coming in today. I’ll talk to you in a week. If you have any questions once 
you leave here feel free to call me. My phone number is listed on the reminder card I just 
gave you. 
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Appendix B 
 
Demographic Survey 
 
Age: _____ 
 
Gender:  Male / Female 
 
Race: please choose one 
  
___ American Indian or Alaska Native  ___ Asian 
 
___ Black or African American   ___ White 
 
___ Native Hawaiian or Other Pacific Islander ___ Other 
 
 
Ethnicity: please choose one 
 
 ___ Hispanic or Latino  ___ not Hispanic or Latino 
 
 
Name of University/College of Attendance: _______________________________ 
 
 
Student Status: 
 
 ___ Full-Time  ___ Part-Time 
 
 
Grade Point Average (GPA): ______ 
 
 
Current year in college: 
 
 ___ Freshman   ___ Sophomore ___ Junior  ___ Senior  
 
 
Greek Membership: please choose one 
 
 ___ Fraternity member  ___ Sorority member  ___ Neither 
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Socioeconomic Status: please choose one (if you are dependent on someone else, like 
your parents, please indicate their socioeconomic status) 
 
___ less than $15,000  ___ $45,000 - $55,000 ___ $85,000 - $95,000 
 
___ $15,000 - $25,000 ___ $55,000 - $65,000 ___$95,000 - $105,000 
 
___ $25,000 - $35,000 ___ $65,000 - $75,000 ___ more than $105,000 
 
___ $35,000 - $45,000 ___ $75,000 - $85,000 
 
 
Stimulant Medication Use:  
Please indicate the method you use to take the drug: 
 
 _____ Orally (pill form) 
 
 _____ Nasally (crushing the pill and snorting it) 
 
 _____ Both 
 
 _____ Other (specify: _________________ ) 
 
 
Do you have a prescription for a stimulant medication? YES / NO 
 
 If yes, what is the name of the medication? _________________________ 
 
 If yes, what is the dosage of the medication? _______________________ 
 
If no, what is the name of the medication you typically use? _________________ 
 
 If no, how much do you typically take (i.e., dosage)? _____________ 
 
 If no, how do you typically acquire the medication? 
 
  _____ From a friend/acquaintance 
 
  _____ Buy it from someone 
 
  _____ Other (specify: ___________________ ) 
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Appendix C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Timeline FollowBack: 
 
Substance Use 
 
Interviewer Manual 
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Procedures for Conducting the Timeline FollowBack Interview: Substance 
Use 
 
General Instructions: (to be read to participant) 
• Today we are going to talk about your alcohol and drug use over the past three months. 
• What we’re going to do is work together to come up with the number of times that you drank 
alcohol or used marijuana, cigarettes, or stimulant medication for each day in the past three 
months. 
• At first this may seem hard, but by using a calendar [show calendar] and a few “tips” to help 
your memory, you’d be surprised how well you can remember things that have happened. 
• Do you have a date book or calendar that you use? If you have an appointment book or a 
daily diary, you can use it to help you recall past events. 
 
IF YES: 
• Do you have it with you today? You can use this to help remember specific days. 
 
IF NO: 
• It’s OK if you don’t have one with you. 
 
• Before we get started I want to remind you that this interview is confidential. We use code 
numbers to identify all the data and none of the information we discuss today will be shared 
with anyone who is not a research staff member from this study. 
 
• Let’s start with yesterday (date) and go back 3 months. Those dates are (date) through (date). 
[Interviewer marks these dates on the calendars and shows participant] 
• Standard holidays, such as Halloween and Thanksgiving, are marked on the calendar to help 
you recall your activities around these times. You can also tell me about personal holidays 
and events, such as birthdays, sports or social events, and so on. 
• Do you have any special holidays or dates you want me to mark on the calendar to help you 
better recall your activities during the past 3 months? We call these anchor days because they 
help to anchor memories of what happened. [Interviewer fills in calendar as appropriate] 
• OK, now I’m going to ask you about your alcohol, marijuana, cigarette, and stimulant 
medication use over the past 3 months. OK? 
 
Best Estimate: 
• We have marked the standard holidays, as well as your own personal holidays or special 
events which we can use to help you recall your drinking and other drug use.. 
• As we fill out the calendar I want you to be as accurate as possible, but I realize that it is hard 
for anyone to recall things with 100% accuracy. So, if you can’t recall, for example, whether 
you did something on a Monday or a Thursday of a certain week, just give it your best guess. 
• If you are not sure whether you drank 10, 11, or 12 drinks, choose the middle of the range. 
So, for 10 to 12 drinks, you would say “11” drinks. 
• The important point here is that 10 to 12 drinks is very different than if you said you drank 
only 1 or 2 drinks or 30 to 35 drinks. Does that make sense? 
• Remember: I am asking you to give your best guess. 
• We measure drinking by what are called standard drinks. 
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                              12 oz. beer (usually 1 can or bottle) 
1 standard drink = 5 oz. glass of wine 
                              1.5 oz. of hard liquor 
 
• So, if you had a double, which has two shots of hard liquor, that would count as 2 drinks. If 
you had a different amount of alcohol, like a 40 or 1/5, just let me know and I’ll calculate how 
many standard drinks that was. Do you think you understand the idea of standard drinks? 
• Ready to begin? 
 
Maximum Amount Consumed: 
• Think about the day on which you consumed the most alcohol in the last 30 days. When was 
that?  
• Now, think about the day on which you consumed the most cigarettes in the last 30 days. 
When was that? 
• And what about stimulant medications? 
  
 [Repeat for each 30-day interval] 
 
IF PARTICIPANT REPORTS NO DRINKING: Just 
to be sure, can you think of any times you drank some beer 
or wine, or hard liquor between (start date) and today? 
 
IF PARTICIPANT REPORTS NO CIGARETTE OR 
STIMULANT MEDICATION USE: Just to be sure, 
can you think of any times you smoked a cigarette or used 
stimulant medications between (start date) and today? 
 
IF DATE IS GIVEN: [continue] 
• For days when you had something to drink, I’ll write the number of drinks you consumed in 
the box for each day on the calendar. I will also do the same thing for cigarettes and 
stimulant medication. 
• How many drinks did you have on the day that you had the most to drink? How many 
cigarettes? How much stimulant medication? [record on answer sheet] 
• We are interested in using the calendar to get a picture of your drinking and drug use over 
each of the past 3 months. So, I will repeat the question for all 3 months on this calendar. 
• What was the greatest amount you consumed on any given day this month? [record # of 
drinks/cigarettes/stimulant medication pills in most recent month] 
• Were there any other days this month that you drank or used that amount? [record # of 
drinks/cigarettes/stimulant medication pills] 
• What was the greatest amount you consumed on any given day last month? [record # of 
drinks/cigarettes/stimulant medication pills for the earlier months] 
• Were there any other days last month (or the earlier months) that you drank or used that 
amount? [record # of drinks/cigarettes/stimulant medication pills] 
 
Other Drinking and Drug Use Activities: 
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• Some people have regular patterns to their drinking and drug use, such as certain days of the 
week are regular drinking days or drug use days. People who have fairly regular drinking 
and drug use patterns can use such patterns to help us fill out the calendar. For example, you 
may have a weekend/weekday change in your drinking, or your drinking or drug use may be 
different depending on the season. 
• What the calendar will do is give you a picture of the dates and patterns of your drinking and 
drug use. 
• Next, we will work our way backwards from today, and fill in the remaining days for each 
month. 
 
[Repeat Probes] 
 
• Just to be sure we’ve covered all the days: 
• Did you drink or use cigarettes, marijuana, or stimulant medications on any other anchor 
days? 
• Before or after anchor days? 
 
Write in additional anchor days/events on the calendar 
that the participant volunteers during the discussion. 
 
MARIJUANA USE: 
• Since it is difficult to get an accurate picture of the quantity of marijuana that people use, I 
am going to ask you to just indicate on which days you used marijuana instead of asking you 
to tell me how much you used on each day. 
• Think about the last 30 days. Did you use any marijuana? 
 
IF YES: 
• Which days in the past month did you use marijuana? 
 
IF NO: 
• Just to be sure, can you think of any times you used marijuana between (start date) and 
today? 
 
 [Repeat for each 30-day interval] 
 
Reviewing the Information: 
• Looking at the calendar, does this look like an accurate and complete picture of your drinking 
and drug use during this time period? 
• Please let me know if there is anything else we should add to this calendar. 
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Appendix D 
 
Stimulant Medication Outcome Expectancy Questionnaire 
 
Instructions: Stimulant medications, such as Ritalin, Adderall, and Concerta, are 
medications used to treat Attention Deficit/Hyperactivity Disorder (ADHD). All of the 
following statements are about the use of these medications but without a prescription. 
Please read each statement and indicate on the scale how much you agree or disagree 
with the statement. Circling 1 means that you strongly disagree with the statement and 
circling 7 means that you strongly agree with the statement. Please keep in mind that 
these statements are regarding the use of the medication even though it has not been 
prescribed. 
 
 
Stimulant medication… 
1. … makes it difficult to fall asleep 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
2. … helps people get less bored by their work 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
3. … helps people be more productive with their schoolwork 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
4. … helps people concentrate better 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
5. … helps people stay awake longer or all night 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
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6. … makes people feel more sociable and outgoing 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
7. … makes people feel anxious 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
8. … makes people feel jittery and shaky 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
9. … makes people feel more focused 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
10. … helps people get their work done more efficiently 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
11. … makes people feel less hungry 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
12. … helps people have a more enjoyable time 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
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13. … makes people feel more energetic 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
14. … makes people feel too focused on something 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
15. … makes people feel less distracted 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
16. … makes people feel happier and more content 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
 
 
17. … makes people feel like they crash after taking it 
 
1 2 3 4 5 6 7 
Strongly 
Disagree  
  Neutral   Strongly 
Agree 
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Appendix E 
 
Effects of Medication 
 
Instructions: Please indicate how much you agree or disagree with each statement. 
 
1. After taking the medication I was able to concentrate better. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
2. After taking the medication I had more energy. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
3. After taking the medication I was able to pay attention better. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
4. After taking the medication I felt jittery. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
5. After taking the medication I was able to focus better. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
6. After taking the medication I was less restless. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
7. After taking the medication I felt wired. 
 
0 1 2 3 4 
Not At All     Very Much 
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8. After taking the medication I could remember information better. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
 
9. After taking the medication I was more interested in what I was doing. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
10. After taking the medication I felt anxious. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
11. After taking the medication I was more efficient during the tasks. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
12. After taking the medication I was less distracted. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
13. After taking the medication I felt on edge (i.e., tense). 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
14. After taking the medication I was less impulsive. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
15. After taking the medication I was less fidgety. 
 
0 1 2 3 4 
Not At All     Very Much 
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16. After taking the medication I felt more relaxed. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
17. After taking the medication I felt like I had tunnel vision (i.e., extremely focused on one 
thing). 
 
0 1 2 3 4 
Not At All     Very Much 
 
18. After taking the medication I was in a better mood. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
19. After taking the medication I was less careless. 
 
0 1 2 3 4 
Not At All     Very Much 
 
 
20. After taking the medication, compared to the first testing session, I think my 
performance: 
 
Got Worse  Remained 
the Same 
 Got Better 
 
 
21. After taking the medication, compared to the first testing session, I think my 
performance on the Numbers Forwards and Backwards test: 
 
Got Worse  Remained 
the Same 
 Got Better 
 
 
22. After taking the medication, compared to the first testing session, I think my 
performance on the Letters and Numbers test: 
 
Got Worse  Remained 
the Same 
 Got Better 
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Appendix F 
 
Digit Span 
 
Digits Forward 
[read to the participant]:  
I am going to say some numbers. Listen carefully, and when I am through, I want you to say 
them right after me. Just say what I say. 
 
** Discontinue after a score of 0 on both trials of any item ** 
Item Response Trial Score Item Score  
(0, 1, or 2) 
1. Trial 1:   1 – 7   
 Trial 2:   6 – 3    
2. Trial 1:   5 – 8 – 2    
 Trial 2:   6 – 9 – 4    
3.  Trial 1:   6 – 4 – 3 – 9    
 Trial 2:   7 – 2 – 8 – 6   
4.  Trial 1:   4 – 2 – 7 – 3 – 1    
 Trial 2:   7 – 5 – 8 – 3 – 6    
5.  Trial 1:   6 – 1 – 9 – 4 – 7 – 3    
 Trial 2:   3 – 9 – 2 – 4 – 8 – 7    
6. Trial 1:   5 – 9 – 1 – 7 – 4 – 2 – 8    
 Trial 2:   4 – 1 – 7 – 9 – 3 – 8 – 6    
7. Trial 1:   5 – 8 – 1 – 9 – 2 – 6 – 4 – 7    
 Trial 2:   3 – 8 – 2 – 9 – 5 – 1 – 7 – 4    
8. Trial 1:   2 – 7 – 5 – 8 – 6 – 2 – 5 – 8 – 4    
 Trial 2:   7 – 1 – 3 – 9 – 4 – 2 – 5 – 6 – 8   
             
    Digits Forward Total Score =  
 
Scoring 
Each item is scored0, 1, or 2 points as follows: 
• 2 points if the examinee passes both trials 
• 1 point if the examinee passes only one trial 
• 0 points if the examinee fails both trials 
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Digits Backward 
[read to the participant]:  
Now I am going to say some more numbers. But this time when I stop, I want you to say them 
backward. For example, if I say 7 – 1 – 9, what would you say? 
 
 If the examinee responds correctly (9 – 1 – 7), say: 
 That’s right. Let’s begin with the first item. 
 
If the examinee responds incorrectly, provide the correct response and say: 
No, you would say 9 – 1 – 7. I said 7 – 1 – 9, so to say it backward, you would say  
9 – 1 – 7. Now try these numbers. Remember, you are to say them backward:  
3 – 4 – 8. 
 
Do not provide any assistance on this example or any of the items. Whether or not the 
examinee responds correctly (8 – 4 – 3), proceed to Trial 1 of Item 1. 
 
** Discontinue after a score of 0 on both trials of any item ** 
Item Response Trial Score Item Score  
(0, 1, or 2) 
1. Trial 1:   2 – 4   
 Trial 2:   5 – 7    
2. Trial 1:   6 – 2 – 9     
 Trial 2:   4 – 1 – 5    
3.  Trial 1:   3 – 2 – 7 – 9     
 Trial 2:   4 – 9 – 6 – 8    
4.  Trial 1:   1 – 5 – 2 – 8 – 6     
 Trial 2:   6 – 1 – 8 – 4 – 3    
5.  Trial 1:   5 – 3 – 9 – 4 – 1 – 8    
 Trial 2:   7 – 2 – 4 – 8 – 5 – 6     
6. Trial 1:   8 – 1 – 2 – 9 – 3 – 6 – 5     
 Trial 2:   4 – 7 – 3 – 9 – 1 – 2 – 8     
7. Trial 1:   9 – 4 – 3 – 7 – 6 – 2 – 5 – 8     
 Trial 2:   7 – 2 – 8 – 1 – 9 – 6 – 5 – 3     
 
     Digits Backward Total Score =  
               
 
Digit Span Total Score =  
 
Scoring 
• Same as Digits Forward 
 
** ASK PARTICIPANT ** 
 
  97 
  
“On a scale from 0 to 10, where 0 is NOT AT ALL and 10 is THE 
MOST, how hard did you try to do well on this test?” 
 
_____________ (write participant’s response here) 
 
Norms 
Ages 18-19:                Ages 20-24: 
Raw Score  Scale Score  Scaled Score      Raw Score 
0 – 3 1 1 0 – 3 
4 – 5 2 2 4 – 5 
6 – 7 3 
Borderline
 
3 6 – 7 
8 – 9 4 4 8 – 9 
10 5 5 10 
11 – 12 6 
Low 
Average 
6 11 – 12 
13 7 7 13 
14 – 15 8 8 14 – 15 
16 9 9 16 
17 – 18 10 10 17 – 18 
19 11 11 19 
20 12 12 20 – 21 
21 – 22 13 
 
 
 
Average 
13 23 
23 14 14 23 
24 – 25 15 15 24 – 25 
26 16 
 
High 
Average 16 26 
27 17 17 27 
28 18 18 28 
29 - 30 19 
 
 
Superior 19 29 - 30 
 
(Scaled Score: M = 10; SD = 3) 
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Appendix G 
 
Letter-Number Sequencing 
 
[read to the participant]: 
I am going to say a group of numbers and letters. After I say them, I want you to tell me the 
numbers first, in order, starting with the lowest number. Then tell me the letters in alphabetical 
order. For example, if I say B – 7, your answer should be 7 – B. The number goes first, then the 
letter. If I say 9 – C – 3, then your answer should be 3 – 9 – C, the numbers in order first, then 
the letters in alphabetical order. Let’s practice. 
 
 6 – F   (6 – F) 
 G – 4   (4 – G) 
 3 – W – 5  (3 – 5 – W) 
 T – 7 – L  (7 – L – T) 
 1 – J – A  (1 – A – J) 
 
** If the examinee makes an error on any Practice Item, correct him or her and repeat the 
instructions as necessary. Even if the examinee fails all Practice Items, continue with the 
subtest. 
  
** Discontinue after scores of 0 on all three trials of an item** 
Item Trial Item (Correct Response in Parentheses) Trial 
Score 
(0 or 1) 
Item Score 
(0, 1, 2, or 3) 
1. 1 L – 2     (2 – L)   
 2 6 – P     (6 – P)   
 3 B – 5     (5 – B)   
2. 1 F – 7 – L     (7 – F – L)   
 2 R – 4 – D    (4 – D – R)   
 3 H – 1 – 8     (1 – 8 – H)   
3. 1 T – 9 – A – 3     (3 – 9 – A – T)   
 2 V – 1 – J – 5      (1 – 5 – J – V)   
 3 7 – N – 4 – L     (4 – 7 – L – N)   
4. 1 8 – D – 6 – G – 1     (1 – 6 – 8 – D – G)   
 2 K – 2 – C – 7 – S     (2 – 7 – C – K – S)   
 3 5 – P –  3 – Y – 9     (3 – 5 – 9 – P – Y)    
5. 1 M – 4 – E – 7 – Q – 2     (2 – 4 – 7 – E – M – Q)   
 2 W – 8 – H – 5 – F – 3     (3 – 5 – 8 – F – H – W)   
 3 6 – G – 9 – A – 2 – S      (2 – 6 – 9 – A – G – S)   
6. 1 R – 3 – B – 4 – Z – 1 – C     (1 – 3 – 4 – B – C – R – Z)   
 2 5 – T – 9 – J – 2 – X – 7      (2 – 5 – 7 – 9 – J – T – X)   
 3 E – 1 – H – 8 – R – 4 – D     (1 – 4 – 8 – D – E – H – R)   
7. 1 5 – H – 9 – S – 2 – N – 6 – A     (2 – 5 – 6 – 9 – A – H – 
N – S) 
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 2 D – 1 – R – 9 – B – 4 – K – 3    (1 – 3 – 4 – 9 – B – D – 
K – R) 
  
 3 7 – M – 2 – T – 6 – F – 1 – Z     (1 – 2 – 6 – 7 – F – M – 
T – Z) 
  
 
 
** ASK EFFORT QUESTION ON NEXT PAGE **     Total Raw Score = 
   
 
 
** ASK PARTICIPANT ** 
“On a scale from 0 to 10, where 0 is NOT AT ALL and 10 is THE 
MOST, how hard did you try to do well on this test?” 
 
_____________ (write participant’s response here) 
 
 
Letter-Number Sequencing Scoring 
• Record the examinee’s response to each trial verbatim, the trial score, the item score, and the 
total subtest raw score. 
• For each trial of an item, score 1 point for each correct response, 0 points for each incorrect 
response. A response is incorrect if a number or letter is omitted or if the numbers or letters 
are not said in the specified sequence. As long as the numbers and letters are recalled in the 
sequence, give credit if the examinee gives the letters in sequence before the numbers. Sum 
the trial scores to obtain the item scores; sum the item scores to obtain the total score. 
• Each item is scored 3, 2, 1, or 0 points as followed: 
3 points if the examinee passes all three trials 
2 points if the examinee passes two trials 
1 point if the examinee passes only one trial 
0 points if the examinee fails all three trials 
Maximum Score: 21 points 
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Norms 
Ages 18-19:                           Ages 20-24: 
Raw Score  Scale Score  Scaled Score      Raw Score 
0 – 2 1 1 0 – 2 
3 2 2 3 
4 3 
Borderline
3 4 
5 4 4 5 
6 5 5 6 
7 6 
Low 
Average 
6 7 
8 7 7 8 
9 8 8 9 
10 9 9 10 
11 10 10 11 
12 11 11 12 
13 12 12 13 
14 13 
 
 
 
Average 
13 14 
15 14 14 15 
16 15 15 16 
17 16 
 
High 
Average 16 17 
18 17 17 18 
19 – 20 18 18 19 – 20 
21 19 
 
 
Superior 19 21 
 
(Scaled Score: M = 10; SD = 3) 
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